<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2108210958
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PREVYMIS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LETERMOVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        884.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD INTERNATIONAL GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD INTERNATIONAL GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Sharp & Dohme B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PREVYMIS is an antiviral prescription medicine that contains the active substance letermovir.</p><p>&nbsp;</p><p>PREVYMIS is a medicine for adults who have recently had a stem cell (bone marrow) transplant or a kidney transplant. The medicine helps stop you from getting ill from CMV (&lsquo;cytomegalovirus&rsquo;).</p><p>&nbsp;</p><p>CMV is a virus. For most people, CMV does not hurt them. However, if your immune system is weak after you get a stem cell transplant or a kidney transplant, you may be at high risk of becoming ill from CMV.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given PREVYMIS if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to letermovir or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you take either of these medicines:</p><p>o&nbsp;&nbsp; pimozide - used for Tourette&rsquo;s syndrome</p><p>o&nbsp;&nbsp; ergot alkaloids (such as ergotamine and dihydroergotamine) - used for migraine headaches.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you take the following herbal product:</p><p>o&nbsp;&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum</em>)</p><p>You should not be given PREVYMIS if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before you are given PREVYMIS.</p><p><strong>&nbsp;</strong></p><p><strong>If you are taking PREVYMIS with cyclosporine, do not take the following medicines:</strong><strong> </strong></p><p>o&nbsp;&nbsp; dabigatran - used for blood clots</p><p>o&nbsp;&nbsp; atorvastatin, simvastatin, rosuvastatin, pitavastatin &ndash;for high cholesterol</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>If you are also taking a medicine for high cholesterol (see list of medicines in section &ldquo;Other medicines and PREVYMIS&rdquo; below) you must tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Your medicine or dose may then need to be changed. See the package leaflet for your other medicine for further information.</p><p>&nbsp;</p><p>Additional blood tests may be needed to monitor the following medicines :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporine, tacrolimus, sirolimus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Voriconazole</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>PREVYMIS is not for use in children and adolescents under 18 years old. This is because PREVYMIS has not been tested in this age group.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Other medicines and PREVYMIS</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because PREVYMIS may affect the way other medicines work, and other medicines may affect how PREVYMIS works. Your doctor or pharmacist will tell you if it is safe to take PREVYMIS with other medicines.</p><p>&nbsp;</p><p>There are some medicines you <strong>must not take </strong>with PREVYMIS (see list under &ldquo;You should not be given PREVYMIS if:&rdquo;).</p><p>There are some additional medicines you<strong> must not take</strong> with PREVYMIS and cyclosporine (see list under &ldquo;If you are taking PREVYMIS with cyclosporine, do not take the following medicines:&rdquo;).</p><p><strong><u>&nbsp;</u></strong></p><p>Also tell your doctor if you are taking any of the following medicines. This is because your doctor may have to change your medicines or change the dose of your medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alfentanil - for severe pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fentanyl - for severe pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quinidine - for abnormal heart rhythms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine, tacrolimus, sirolimus - used to prevent transplant rejection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; voriconazole - for fungal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; statins, such as atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin - for high cholesterol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glyburide, repaglinide - for high blood sugar</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, phenobarbital, phenytoin - for fits or seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dabigatran, warfarin - used to thin the blood or for blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; midazolam &ndash; used as a sedative&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amiodarone - used to correct irregular heartbeats</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral contraceptive steroids-for birth control</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; omeprazole, pantoprazole &ndash; for stomach ulcers and other stomach<br />problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nafcillin - for bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin, rifampicin - for mycobacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thioridazine - for psychiatric disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bosentan - for high blood pressure in the vessels in the lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; efavirenz, etravirine, nevirapine, lopinavir, ritonavir - for HIV</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; modafinil - for wakefulness</p><p>&nbsp;</p><p>You can ask your doctor or pharmacist for a list of medicines that may interact with PREVYMIS.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. PREVYMIS is not recommended in pregnancy. This is because it has not been studied in pregnancy and it is not known if PREVYMIS will harm your baby while you are pregnant.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>If you are breast‑feeding or are planning to breast-feed, tell your doctor before taking this medicine. Breast-feeding is not recommended while taking PREVYMIS. This is because it is not known if PREVYMIS gets in your breast milk and will be passed to your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>PREVYMIS may have minor influence on your ability to drive and use machines (see section 4 Possible Side Effects below). Some patients have reported fatigue (feeling very tired) or vertigo (feeling like you are spinning) during treatment with PREVYMIS. If you experience any of these effects, do not drive or use machines until the effect wears off.</p><p>&nbsp;</p><p><strong>PREVYMIS contains sodium</strong></p><p>PREVYMIS contains sodium. If you are on a low sodium diet, talk to your doctor before you are given this medicine.</p><p>&nbsp;</p><p>Each 240&nbsp;mg vial contains 23&nbsp;mg sodium (main component of cooking/table salt). This is equivalent to 1.15% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>PREVYMIS contains cyclodextrin</strong></p><p>Each 240&nbsp;mg dose (12&nbsp;mL vial) of this medicine contains 1800&nbsp;mg cyclodextrin.</p><p>&nbsp;</p><p>If you have a kidney disease, talk to your doctor before you receive this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The recommended dose of PREVYMIS is 480 mg once a day. If you also take cyclosporine, your doctor will decrease the dose of PREVYMIS to 240 mg once a day.</p><p>You will get PREVYMIS as an infusion (drip) into a vein and it will take about 1 hour. You will get PREVYMIS once a day.</p><p>&nbsp;</p><p>If you are given more PREVYMIS than you should</p><p>If you think you have been given too much PREVYMIS, tell your doctor straight away.</p><p>&nbsp;</p><p>If you miss your appointment to get PREVYMIS</p><p>It is very important that you do not miss or skip doses of PREVYMIS.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss your appointment to get PREVYMIS, call your doctor straight away to reschedule your appointment.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10 people</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting)</p><p>&nbsp;</p><p><strong>Uncommon: </strong>may affect up to 1 in 100 people</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction (hypersensitivity) &ndash; the signs may include wheezing, difficulty breathing, rashes or hives, itchiness, swelling.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in taste</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling like you are spinning (vertigo)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormalities in laboratory tests of liver function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood creatinine - shown in blood tests</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired (fatigue)</p><p>&nbsp;</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance and Drug Safety Centre (NPC). SFDA . By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30&deg;C. Store in original carton to protect from light.</p><p>&nbsp;</p><p>Chemical and physical in-use stability has been demonstrated for 48 hours at 25 &deg;C and for 48 hours at 2 to 8 &deg;C.</p><p>&nbsp;</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 &deg;C, unless dilution has taken place in controlled and validated aseptic conditions.</p><p>&nbsp;</p><p>Any unused portion of the infusion solution should be discarded.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is letermovir. Each vial contains 240 mg letermovir. Each mL of concentrate contains 20 mg/mL.</p><p>The other ingredients are: hydroxypropylbetadex (cyclodextrin), sodium chloride, sodium hydroxide (E524), water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                PREVYMIS 240 mg concentrate for solution for infusion is a clear, colourless liquid. The 240 mg  concentrate for solution for infusion is packaged in clear, glass vials. Each vial is packaged in a carton.

 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Merck Sharp &amp; Dohme BV</p><p>Waarderweg 39<br />PO Box 581&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />2031 BN, 2003 PC<br />Haarlem&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>MSD International GmbH</p><p>T/A MSD Ireland (Carlow)</p><p>Dublin Road,</p><p>Carlow, Co. Carlow</p><p>Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Nov 2023.


To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA
o Fax: +966-11-205-7662
o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.
o Toll free phone: 8002490000
o E-mail: npc.drug@sfda.gov.sa
o Website: www.sfda.gov.sa/npc
•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.

Council of Arab Health Ministers 
Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food and Drug Authority









The following information is intended for healthcare professionals only:

Administration instructions for PREVYMIS concentrate for solution for infusion

PREVYMIS concentrate for solution for infusion vials are for single use only. Discard any unused portion.

Preparation
PREVYMIS concentrate for solution for infusion must be diluted prior to intravenous (IV) use. The preparation and administration instructions are the same for either dose.

•	Inspect vial contents for discolouration and particulate matter prior to dilution. PREVYMIS concentrate for solution for infusion is a clear, colourless solution. Do not use the vial if the solution is discoloured or contains visible particles.
•	Do not shake PREVYMIS vial.
•	Add one or two vials (either 12 mL (240 mg dose) or 24 mL (480 mg dose), respectively) of PREVYMIS concentrate for solution for infusion to a 250 mL pre-filled IV bag containing either 0.9% sodium chloride or 5% dextrose, and mix the diluted solution by gentle inversion. Do not shake.
•	Once diluted, the solution of PREVYMIS is clear, and ranges from colourless to yellow. Variations of colour within this range do not affect the quality of the product. The diluted solution should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. Discard if discolouration or visible particles are observed. If one vial (for 240 mg dose) or two vials (for 480 mg dose)are added to a 250 mL IV diluent bag, the final concentration ranges of letermovir would be 0.9 mg/mL  and 1.8 mg/mL, respectively


 
Administration
•	Administer as an intravenous infusion only. Do not administer as an intravenous push or bolus.
•	After dilution, administer PREVYMIS via intravenous infusion via peripheral or central venous catheter using a total time of approximately 60 minutes. Administer the entire contents of the IV bag.

Compatible intravenous solutions and other medicinal products
•	PREVYMIS concentrate for solution for infusion is compatible with 0.9% sodium chloride and 5% dextrose solutions.
•	Compatible medicinal products are listed below.
•	This medicinal product must not be mixed with other medicinal products except those listed below.
•	PREVYMIS should not be co-administered through the same intravenous line (or cannula) with other medicinal products and diluent combinations except those listed below.

List of compatible medicinal products when PREVYMIS and medicinal products* are prepared in 0.9% sodium chloride
•	Ampicillin sodium	•	Fluconazole
•	Ampicillin sodium/Sulbactam sodium	•	Human insulin
•	Anti-thymocyte globulin	•	Magnesium sulfate
•	Caspofungin	•	Methotrexate
•	Daptomycin	•	Micafungin
•	Fentanyl citrate

*Refer to the prescribing information to confirm compatibility of simultaneous co-administration.

List of compatible medicinal products when PREVYMIS and medicinal products* are prepared in 5% dextrose
•	Amphotericin B (lipid complex)†	•	Hydrocortisone sodium succinate
•	Anidulafungin	•	Morphine sulfate
•	Cefazolin sodium	•	Norepinephrine bitartrate
•	Ceftaroline	•	Pantoprazole sodium
•	Ceftriaxone sodium	•	Potassium chloride
•	Doripenem	•	Potassium phosphate
•	Famotidine	•	Tacrolimus
•	Folic acid	•	Telavancin
•	Ganciclovir sodium	•	Tigecycline
*Refer to the prescribing information to confirm compatibility of simultaneous co-administration.
†Amphotericin B (lipid complex) is compatible with PREVYMIS. However, Amphotericin B (liposomal) is incompatible (see section 6.2).

Compatible intravenous bags and infusion set materials

PREVYMIS is compatible with the following intravenous bags and infusion set materials. Any intravenous bags or infusion set materials not listed below should not be used.

Intravenous bag materials
Polyvinyl chloride (PVC), ethylene vinyl acetate (EVA) and polyolefin (polypropylene and polyethylene)

Infusion set materials
PVC, polyethylene (PE), polybutadiene (PBD), silicone rubber (SR), styrene–butadiene copolymer (SBC), styrene-butadiene-styrene copolymer (SBS), polystyrene (PS)

Plasticizers
Diethylhexyl-phthalate (DEHP), tris (2-ethylhexyl) trimellitate (TOTM), butyl benzyl phthalate (BBP)
 
Catheters
Radiopaque polyurethane

Incompatible medicinal products
PREVYMIS concentrate for solution for infusion is physically incompatible with amiodarone hydrochloride, amphotericin B (liposomal), aztreonam, cefepime hydrochloride, ciprofloxacin, cyclosporine, diltiazem hydrochloride, filgrastim, gentamicin sulfate, levofloxacin, linezolid, lorazepam, midazolam HCl, mycophenolate mofetil hydrochloride, ondansetron, palonosetron.

Incompatible IV bags and infusion set materials
PREVYMIS is incompatible with polyurethane-containing IV administration set tubing.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">بريفيميس هو دواء &nbsp;يُصرف بوصفة طبية مضاد للفيروسات يحتوي على المادة الفعالة ليتيرموفير.</p><p dir="RTL">يُستخدم بريفيميس لدى البالغين ممن خضعوا مؤخّرًا لعملية زرع الخلايا الجذعية (زرع نخاع العظم) أو زراعة الكلى. يساعد هذا الدواء على وقايتك من الإصابة بمرض سي إم في CMV (الفيروس المُضخّم للخلايا).</p><p dir="RTL">CMV الفيروس المضخم للخلايا هو فيروس. بالنسبة لمعظم الناس ، لا يؤذيهم الفيروس المضخم للخلايا. ومع ذلك ، إذا كان جهازك المناعي ضعيفا بعد إجراء عملية زرع الخلايا الجذعية أو زراعة الكلى ، فقد تكون معرضا لخطر الإصابة بالمرض من الفيروس المضخم للخلايا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; كان لديك حساسية نحو ليتيرموفير أو أيّ من المكونات الأخرى لهذا الدواء (المدرجة في الفقرة رقم 6).<br />&bull; كنت تستخدم أحد الأدوية التالية:<br />&nbsp;&nbsp; o&nbsp; بيموزيد - يستخدم لعلاج متلازمة توريت<br />&nbsp;&nbsp; o&nbsp; قلويدات الإرغوت (مثل الإرغوتامين و ديهيدروإرجوتامين) - يستخدم لعلاج الصداع النصفي.</p><p dir="RTL">&bull;كنت تتناول المنتجات العشبية التالية: نبتة القديس يوحنا (Hypericum perforatum)</p><p dir="RTL">لا ينبغي أن تُعطى بريفيميس إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الصيدلي أو الممرض قبل إعطاءك بريفمس .<br /><strong>إذا كنت تستخدم بريفيميس مع سيكلوسبورين، لا تستخدم الأدوية التالية:</strong><br />&nbsp;&nbsp; o دابيغاتران - يُستخدم لعلاج جلطات الدم<br />&nbsp;&nbsp; o أتورفاستاتين، سيمفاستاتين، روسوفاستاتين، بيتافاستاتين &ndash; لعلاج ارتفاع الكوليسترول في الدم</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><br />إذا كنت تتناول أيضًا دواء لعلاج ارتفاع نسبة الكوليسترول في الدم (انظر قائمة الأدوية في فقرة &quot;أدوية أخرى و بريفيميس &quot; أدناه) ، يجب عليك إخبار طبيبك على الفور إذا تعرّضت لآلام أو أوجاع في العضلات مجهولة السبب وعلى الأخص إذا كنت تشعر بتوعك أو تعاني من الحمى. قد يحتاج الدواء أو الجرعة إلى تغيير. راجع نشرة العبوة للحصول على مزيد من المعلومات.</p><p dir="RTL">قد يتطلب الأمر إجراء فحوصات دم إضافية لمراقبة المنتجات الطبية التالية:</p><p dir="RTL">&bull; السيكلوسبورين، تاكروليموس، سيروليموس<br />&bull; فوريكونازول<br /><br /><strong>الأطفال والمراهقين</strong><br />بريفيميس غير مُعَدٍّ للاستخدام لدى الأطفال والمراهقين دون سن 18 عامًا. وذلك لأنه لم تتم دراسة بريفيميس في هذه الفئة العمرية.<br /><br /><strong>الأدوية الأخرى و بريفيميس</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو قد تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى. وذلك لأن بريفيميس قد يؤثر على طريقة عمل الأدوية الأخرى، والأدوية الأخرى قد تؤثر على كيفية عمل بريفيميس. سيخبرك طبيبك أو الصيدلي إذا كان من الآمن تناول بريفيميس مع أدوية أخرى.</p><p dir="RTL">هناك بعض الأدوية التي يجب ألا تتناولها مع بريفيميس ( انظر القائمة تحت عنوان &quot; يجب ألا يتم إعطاؤك بريفيميس إذا).</p><p dir="RTL">هناك بعض الأدوية الإضافية التي يجب ألا تتناولها مع بريفيميس و السيكلوسبورين (انظر القائمة تحت عنوان &quot;إذا كنت تتناول بريفيميس مع السيكلوسبورين ، فلا تتناول الأدوية التالية:&quot;).</p><p dir="RTL">أخبر طبيبك أيضًا إذا كنت تتناول أيًّا من الأدوية التالية. وذلك لأن طبيبك قد يضطر إلى تغيير الأدوية أو جرعة الأدوية الخاصة بك:</p><p dir="RTL">&bull; ألفنتانيل &ndash; لتسكين الألم الشديد<br />&bull; فنتانيل - لتسكين الألم الشديد<br />&bull; الكينيدين &ndash; لعلاج اضطراب نظم القلب.<br />&bull; السيكلوسبورين، تاكروليموس، سيروليموس - تُستخدم لمنع رفض الزرع<br />&bull; فوريكونازول&nbsp; - لعلاج العدوى الفطرية<br />&bull; الستاتينات، مثل أتورفاستاتين، فلوفاستاتين، روسوفاستاتين، سيمفاستاتين، برافاستاتين، بيتافاستاتين -&nbsp; لعلاج ارتفاع الكوليسترول في الدم<br />&bull; غليبوريد، ريباغلينيد &ndash; لعلاج ارتفاع نسبة السكر في الدم<br />&bull; الفينيتوين كاربامازيبين، فينوباربيتال &ndash; لعلاج النوبات أو التشنجات<br />&bull; دابيغاتران، الوارفارين - يستخدم لزيادة سيولة الدم أو لعلاج التجلطات<br />&bull; ميدازولام - يستخدم كمُسكّن<br />&bull; الأميودارون - يستخدم لتصحيح دقات القلب الغير منتظمة</p><p>Arabic translation.&nbsp;</p><p dir="RTL">&bull; موانع الحمل الفموية - لتحديد النسل<br />&bull; أوميبرازول، بانتوبرازول &ndash; لعلاج قرحة المعدة وغيرها من مشاكل المعدة</p><p dir="RTL">&bull; نافيسلين - للالتهابات البكتيرية</p><p dir="RTL">&nbsp;&bull;ريفابوتين، ريفامبيسين - للالتهابات الفطرية</p><p dir="RTL">&bull; ثيوريدازين - للاضطرابات النفسية</p><p dir="RTL">&bull; بوسينتان - &nbsp;لارتفاع ضغط الدم في الأوعية في الرئتين</p><p dir="RTL">&bull; إيفيفيرينز، إيترافرين، نيفيرابين، لوبينافير، ريتونافير - لفيروس نقص المناعة البشرية</p><p dir="RTL">&nbsp;&bull; مودافينيل - لليقظة</p><p dir="RTL">يمكنك أن تسأل طبيبك أو الصيدلي عن قائمة الأدوية التي قد تتداخل مع بريفمس<br /><br /><strong>الحمل</strong><br />إذا كنت حامل، أو تعتقدين أنك قد تكونين حامل، أو تخططين لإنجاب طفل، فاستشيري طبيبك قبل استخدام هذا الدواء. لا يُنصح باستخدام بريفيميس أثناء الحمل. هذا لأنه لم تتم دراسته أثناء الحمل ولا يُعرف إذا كان بريفيميس سيؤذي طفلك أثناء الحمل.<br /><br /><strong>الرضاعة الطبيعية</strong><br />إذا كنت ترضعين طفلك أو تخططين للرضاعة الطبيعية، أخبري طبيبك قبل استخدام هذا الدواء. لا يوصى بالرضاعة الطبيعية أثناء تناول بريفيميس. هذا لأنه من غير المعروف إذا كان بريفمس &nbsp;يُفرز في حليب الثدي وإحتمال إنتقاله إلى طفلك.<br /><br /><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يكون&nbsp; لـبريفيميس تأثير بسيط على قدرتك على القيادة واستخدام الآلات (انظر الفقرة 4 - الأعراض الجانبية المحتملة أدناه). أبلغ بعض المرضى عن إصابتهم بالتعب (الشعور بالإرهاق الشديد) أو الدوار (الشعور بأنك تدور) أثناء العلاج ببريفيميس. إذا واجهت أيًّا من هذه التأثيرات، فلا تَسُقْ السيارة أو تستخدم الآلات حتى يختفي التأثير.<br /><strong>بريفيميس يحتوي على الصوديوم</strong><br />بريفيميس يحتوي على الصوديوم. إذا كنت تتبع نظامًا غذائيًّا منخفض الصوديوم، فتحدث إلى طبيبك قبل إعطائك هذا الدواء.</p><p dir="RTL">تحتوي كل قارورة من بريفيميس 240 ملغم على 23 ملغم من الصوديوم (المكون الرئيسي لملح الطعام). هذا يعادل 1,15٪ من الحدّ الأقصى الموصى به من المدخول الغذائي اليومي من الصوديوم للبالغين.<br /><br /><strong>بريفيميس يحتوي على سيكلوديكسترين</strong><br />تحتوي كل قارورة من<strong> </strong>هذا الدواء 240 ملغم (12 مل قارورة)&nbsp; على 1800 ملغم سيكلوديكسترين.</p><p dir="RTL">إذا كنت تعاني من مرض في الكلى، تحدث إلى طبيبك قبل أن تتلقى هذا الدواء.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة الموصى بها من بريفمس &nbsp;هي 480 ملغم مرة واحدة في اليوم. إذا كنت تتناول سيكلوسبورين أيضًا، فسيقوم طبيبك بتخفيض جرعة بريفمس &nbsp;إلى 240 ملغم مرة واحدة يوميًّا.</p><p dir="RTL">سيتم إعطاؤك بريفمس &nbsp;بواسطة التسريب (بالتنقيط) في الوريد وسوف يستغرق ذلك حوالي ساعة واحدة. سوف تتلقى بريفمس &nbsp;مرة واحدة في اليوم.<br /><br /><strong>إذا تم إعطاؤك من بريفمس &nbsp;أكثر مما يجب</strong><br />إذا كنت تعتقد أنه قد تم إعطاؤك أكثر مما يجب من بريفمس ، أخبر طبيبك على الفور.<br /><br /><strong>إذا فاتك أحد المواعيد لتلقي الدواء</strong><br />من المهم جدًّا عدم تفويت أو تخطي جرعات من بريفمس .<br />&bull; إذا فاتك أحد المواعيد لتلقي بريفمس ، فاتصل بطبيبك على الفور لإعادة جدولة موعدك.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، مع أنها لا تحدث لدى جميع من يتناوله.</p><p dir="RTL"><strong>شائعة:</strong> قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص<br />&bull; إسهال<br />&bull; الشعور بالمرض (الغثيان)<br />&bull; المرض (القيء)</p><p dir="RTL"><strong>غير شائعة:</strong> قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص<br />&bull; تفاعلات تحسسية (فرط الحساسية) - قد تشمل العلامات الصفير، وصعوبة التنفس، والطفح الجلدي أو الشرى، والحكة، والتورم.<br />&bull; فقدان الشهية<br />&bull; التغيرات في حاسة التذوق<br />&bull; صداع الراس<br />&bull; الدوار (الشعور وكأنك تدور)<br />&bull; ألم المعدة<br />&bull; نتائج غير طبيعية في فحوصات وظائف الكبد.<br />&bull; تشنجات العضلات<br />&bull; ارتفاع الكرياتينين في الدم - كما يظهر في فحوصات الدم<br />&bull; الشعور بالتعب الشديد (الإعياء)<br /><br /><strong>الإبلاغ عن الأعراض الجانبية</strong><br />إذا تعرّضت لأي أعراض جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عن طريق (المركز الوطني للتيقظ والسلامة الدوائية التابع للهيئة العامة للغذاء والدواء)&nbsp; . من خلال الإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدرج على علبة الكرتون والقارورة بعد كلمة &quot;EXP &quot;.</p><p dir="RTL">يُحفظ في درجة حرارة أقل من 30 درجة مئوية. احفظه داخل الكرتون الأصلي للحماية من الضوء.</p><p dir="RTL">ثبت الاستقرار الكيميائية والفيزيائية أثناء الاستخدام لمدة 48 ساعة في درجة حرارة 25 درجة مئوية ولمدة 48 ساعة في درجة حرارة 2 إلى 8 درجة مئوية.</p><p dir="RTL">من وجهة النظر الأحيائية الدقيقة (الميكروبيولوجية) ، يجب استخدام المنتج على الفور. إذا لم يتم استخدامه على الفور، فإن أوقات وظروف التخزين أثناء الاستخدام هي مسؤولية المستخدم ولن تستغرق عادة أكثر من 24 ساعة عند درجة حرارة 2 إلى 8 درجة مئوية، ما لم يحدث التخفيف في ظروف معقمة يتم التحكم فيها والتحقق من صحتها.</p><p dir="RTL">يجب التخلص من أي جزء مُتبقِ غير مستخدم من محلول التسريب.</p><p>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. من شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتويات ليتيرموفير</strong><br />المادة الفعالة هي ليتيرموفير. تحتوي كل فيال &nbsp;على 240 ملغم ليتيرموفير . يحتوي كل مل من المحلول المُركّز على 20 ملغم /مل.<br />المكونات الأخرى هي: هيدروكسي بروبيل بيتاديكس (سيكلوديكسترين)، كلوريد الصوديوم، هيدروكسيد الصوديوم (E524)، الماء المخصص للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>محلول بريفمس &nbsp;240 ملغم المُركز للتسريب الوريدي هو محلول صافٍ عديم اللون، يتوفر في فيال &nbsp;زجاجية شفافة. كل علبة كرتون تحتوي على عدد فيال واحدة.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق :</strong></p><p dir="RTL">ميرك شارب و دوم بي في</p><p dir="RTL">واردرويج ٣٩</p><p dir="RTL">صندوق بريد 581</p><p dir="RTL">٢٠٣١ بي ان ، &nbsp;2003 بي سي</p><p dir="RTL">هارلم</p><p dir="RTL">هولندا</p><p dir="RTL"><br /><br /><strong>الشركة الصانعة:</strong></p><p dir="RTL">إم إس دي العالمية، شركة ذات مسؤوولية محدودة</p><p dir="RTL">تي/أي إم إس دي إيرلندا (كارلو)</p><p dir="RTL">طريق دبلن، كارلو، كو. كارلو</p><p dir="RTL">إيرلندا&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ نوفمبر 2023





للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية، الهيئة العامة للغذاء والدواء
فاكس: +966-11-205-7662
للاتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات . هاتف: +966-11-20382222	
تحويلة: 2317-2356-2353-2354-2334-2340
الهاتف المجاني: 8002490000  
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: www.sfda.gov.sa/npc
•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.

(إنّ هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إنّ الطبيب والصيدلي هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
واتحاد الصيادلة العرب
تمت الموافقة على نشرة معلومات المريض هذه من قبل الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية


المعلومات التالية موجهة للمتخصصين في الرعاية الصحية
الإرشادات الخاصة بطريقة إعطاء محلول بريفمس  المُركز للتخفيف للحقن بالتسريب الوريدي .
فيال  محلول بريفمس  المُركز للتخفيف للحقن بالتسريب الوريدي مُعدّة للاستخدام الفردي فقط. تخلّص من أيّ جزء غير مستخدم.
التحضير
يجب تخفيف محلول بريفمس  المُركز قبل حقنه بالتسريب الوريدي.  تعليمات التحضير والإعطاء لا تختلف بين الجرعتين. 
• قم بفحص محتويات فيال  للتأكد من خلوها من الجسيمات وأي تغيّر في اللون قبل التخفيف. محلول بريفمس  المُركز للتخفيف للحقن بالتسريب الوريدي هو محلول صافٍ عديم اللون. لا تستخدم فيال  إذا لاحظت أي تغّير في لون المحلول أو وجود جسيمات مرئية.
• تجنّب رجّ فيال  بريفمس .
• أضف محتوى فيال  واحدة أو اثنتين (إما 12 مل (جرعة 240 مجم) أو 24 مل (جرعة 480 مجم)، على التوالي) من محلول بريفمس  المركز إلى كيس محلول التسريب الوريدي المُعبّأ مسبقًا ويحتوي 250  مل من 0.9٪ كلوريد الصوديوم أو 5 ٪ دكستروز، وقم بمزج المحلول المخفف عن طريق تقليبه بلطف.  لا ترجه. 
• بمجرد تخفيفه، يكون محلول بريفمس  صافٍ، ويتراوح في اللون من عديم اللون إلى اللون الأصفر. لا تؤثر الاختلافات في اللون داخل هذا النطاق على جودة المنتج. يجب فحص المحلول المُخفّف بصريًا بحثًا عن الجسيمات وتغير اللون قبل الإعطاء، كلما سمحت بذلك طبيعة المحلول وكيس المحلول الوريدي. تخلّص من المحلول إذا لاحظت أي تغير في اللون أو جزيئات مرئية. إذا تمت إضافة قارورة واحدة (لجرعة 240 مجم) أو قارورتين (لجرعة 480 مجم) إلى كيس محلول التخفيف بحجم 250 مل، فإن نطاقات التركيز النهائية من ليتيرموفير ستكون 0,9 مجم/مل و 1,8 مجم/مل، على التوالي.

طريقة الاستخدام
• قم بحقنه بالتسريب الوريدي فقط. لا يُحقن بالوريد حقنًا مباشرًا ، أو كدفعة واحدة.
• قم بإعطاء بريفمس  بعد التخفيف عن طريق الحقن بالتسريب الوريدي باستخدام قسطرة وريدية محيطية 
  أو مركزية على مدى 60 دقيقة تقريبًا. تأكد من إعطاء محتوى كيس محلول التسريب بالكامل. 

التوافق مع المحاليل الوريدية والمنتجات الدوائية الأخرى
• يتوافق محلول بريفمس  للتخفيف للحقن بالتسريب الوريدي مع محاليل 0,9٪ من كلوريد الصوديوم  ومحاليل الدكستروز 5٪. 
• المنتجات الطبية المتوافقة مذكورة أدناه.
• يجب عدم خلط هذا المنتج الطبي مع المنتجات الطبية الأخرى باستثناء المنتجات المذكورة أدناه.
• يجب عدم حقن بريفمس  في نفس أنبوب الحقن الوريدي (أو القنية) بالتزامن مع منتجات طبية أخرى  ومزيج من المحاليل المُخفِّفة باستثناء تلك المذكورة أدناه.
قائمة بالمنتجات الطبية المتوافقة* عند تحضيرها وتحضير بريفمس  في محلول  كلوريد الصوديوم 0,9٪
• أمبيسيلين الصوديوم				 • الفلوكونازول
• أمبيسيلين الصوديوم/سولباكتام الصوديوم	 • الأنسولين البشري
• الجلوبيولين المضاد لخلايا التيموس 		 • كبريتات المغنسيوم
• كاسبوفانجين					 • الميثوتريكسيت
• دابتوميسين					 • ميكافنجين
• فنتانيل سترات
* يرجى الرجوع إلى معلومات وصف الدواء للتأكد من التوافق أثناء الحقن المشترك. 

قائمة بالمنتجات الطبية المتوافقة* عند تحضيرها وتحضير بريفمس  في دكستروز 5٪
• الأمفوتريسين B (مُعقّد شحمي) †		 • هيدروكورتيزون صوديوم سكسينات
• أنيدولافونجين 					 • سلفات المورفين		
• سيفازولين الصوديوم  				 • نورإبينيفرين بايتارتاريت				
• سيفتارولين  					 • بانتوبرازول صوديوم
• سيفترياكسون صوديوم				 • كلوريد البوتاسيوم
• دوريبينيم					 • فوسفات البوتاسيوم
• فاموتيدين					 • التاكروليموس
• حمض الفوليك					 • تيلافانسين
• جانسيكلوفير الصوديوم				 • تيجيسيكلين
* يرجى الرجوع إلى معلومات وصف الدواء للتأكد من التوافق أثناء الحقن المشترك. 
† يتوافق الأمفوتريسين B (مُعقّد شحمي) مع بريفمس . ومع ذلك، فإن الأمفوتريسين B (بتركيبة 
الجسيمات الشحمية) لا متوافق (انظر القسم 6,2).
أكياس المحاليل الوريدية وأنابيب الحقن المتوافقة 
يتوافق بريفمس  مع أكياس المحاليل الوريدية وأنابيب الحقن التالية. ينبغي عدم استخدام أي أكياس محاليل وريدية أو أنابيب حقن غير مدرجة أدناه.
المواد المكوّنة لأكياس المحاليل الوريدية
بولي فينيل كلوريد (PVC)، إيثيلين فينيل أسيتات (EVA) وبولي أوليفين (بولي بروبيلين وبولي إيثيلين)

المواد المكوّنة لأنابيب الحقن الوريدي 
PVC، البولي إيثيلين (PE)، بولي بوتاديين (PBD)، مطاط السيليكون (SR)، كوبوليمر ستيرين - بوتادين (SBC)، كوبوليمر ستيرين - بوتادين - ستايرين (SBS)، بوليسترين (PS)

المُلَدّنات
ثنائي إيثيل هكسيل - فثالات (DEHP)، تريس (2 - إيثيل هكسيل) تريميليتات (TOTM)، بوتيل بنزيل فثالات (BBP)

القثاطر
البولي يوريثين الظليل للأشعة  

منتجات طبية غير متوافقة
لا يتوافق محلول بريفمس  للتخفيف للحقن بالتسريب الوريدي فيزيائيًا مع أميودارون هيدروكلوريد، الأمفوتيريسين (ليبوسومال)، آزتريونام، سيفيبيم هيدروكلوريد، سيبروفلوكساسين، سيكلوسبورين، ديلتيازيم هيدروكلوريد، فيلغراستيم، جنتاميسين سلفات، ليفوفلوكساسين، لينزوليد، لورازيبام، ميدازولام هيدروكلوريد، ميكوفينوليت موفيتيل هيدروكلوريد، أوندانسيترون، بالونوسيترون.

أكياس محاليل وريدية وأنابيب تسريب وريدي غير متوافقة
لا يتوافق محلول بريفمس  للتخفيف للحقن بالتسريب الوريدي مع أنابيب الحقن الوريدي المحتوية على مادة البولي يوريثين.
يجب التخلص من أي منتج طبي غير مستخدم أو نفايات طبية وفقًا للمتطلبات المحلية.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PREVYMIS 240 mg concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PREVYMIS 240 mg concentrate for solution for infusion

Each vial contains 240 mg (12 mL per vial) of letermovir.
Each mL contains 20 mg of letermovir.

Excipients with known effect

This medicinal product contains 23 mg (1 mmol) sodium per 240 mg vial.

Each 240 mg dose (12 mL vial) of this medicinal product contains 1800 mg hydroxypropylbetadex (cyclodextrin).

For additional information, see section 4.2.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate)
Clear, colourless liquid
pH between 7 and 8
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</strong></p><p>&nbsp;</p><p>PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).</p><p>&nbsp;</p><p>PREVYMIS is indicated for prophylaxis of CMV disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-].</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antiviral agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PREVYMIS should be initiated by a physician experienced in the management of patients who have had an allogeneic haematopoietic stem cell transplant or kidney transplant.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>PREVYMIS is also available for oral administration (240&nbsp;mg film-coated tablets).</p><p>&nbsp;</p><p>PREVYMIS tablets and concentrate for solution for infusion may be used interchangeably at the discretion of the physician, and no dose adjustment is necessary.</p><p><em>&nbsp;</em></p><p>The recommended dose of PREVYMIS is 480&nbsp;mg once daily.</p><p>&nbsp;</p><p><em>HSCT</em></p><p>PREVYMIS should be started after HSCT. PREVYMIS may be started on the day of transplant and no later than 28 days post-HSCT. PREVYMIS may be started before or after engraftment. Prophylaxis with PREVYMIS should continue through 100 days post-HSCT.</p><p><s>&nbsp;</s></p><p>Prolonged PREVYMIS prophylaxis beyond 100 days post-HSCT may be of benefit in some patients at high risk for late CMV reactivation (see section 5.1). The safety and efficacy of PREVYMIS use for more than 200 days has not been studied in clinical trials.</p><p>&nbsp;</p><p><em>Kidney transplant</em></p><p>PREVYMIS should be started on the day of transplant and no later than 7 days post-kidney transplant and continued through 200 days post-transplant.</p><p><em><u>&nbsp;</u></em></p><p><em>Dose</em><em> adjustment</em><em> </em></p><p>If PREVYMIS is co-administered with cyclosporine, the dose of PREVYMIS should be decreased to 240&nbsp;mg once daily (see sections 4.5 and 5.2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If cyclosporine is initiated after starting PREVYMIS, the next dose of PREVYMIS should be decreased to 240&nbsp;mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If cyclosporine is discontinued after starting PREVYMIS, the next dose of PREVYMIS should be increased to 480&nbsp;mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If cyclosporine dosing is temporarily interrupted due to high cyclosporine levels, no dose adjustment of PREVYMIS is needed.</p><p><em><u>&nbsp;</u></em></p><p><em>Missed dose</em></p><p>If a dose is missed, it should be given to the patient as soon as possible. If it is time for the next dose, skip the missed dose and go back to the regular schedule. Do not double the next dose or give more than the prescribed dose.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment of PREVYMIS is required based on age (see sections 5.1 and 5.2)<em>.</em></p><p><strong><u>&nbsp;</u></strong></p><p><em>Hepatic impairment</em></p><p>No dose adjustment of PREVYMIS is required based on mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) hepatic impairment. PREVYMIS is not recommended for patients with severe (Child-Pugh Class C) hepatic impairment (see section 5.2)<em>.</em></p><p><strong><u>&nbsp;</u></strong></p><p><em>Combined hepatic and renal impairment</em></p><p>PREVYMIS is not recommended in patients with moderate hepatic impairment combined with moderate or severe renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment of PREVYMIS is recommended for patients with mild, moderate, or severe renal impairment<em>.</em> No dose recommendation can be made for patients with end stage renal disease (ESRD) with or without dialysis. Efficacy and safety has not been demonstrated for patients with ESRD.</p><p><strong><u>&nbsp;</u></strong></p><p>PREVYMIS concentrate for solution for infusion contains hydroxypropylbetadex. The anticipated clinical exposure to hydroxypropylbetadex with intravenously administered letermovir is expected to be approximately 3600&nbsp;mg/day for a letermovir dose of 480&nbsp;mg. There were no cases of kidney injury caused by hydroxypropylbetadex in human studies of intravenously administered letermovir with treatment durations of up to 47 days. In patients with moderate or severe renal impairment (creatinine clearance less than 50&nbsp;mL/min) receiving PREVYMIS, accumulation of hydroxypropylbetadex, could occur (see section 5.3). Serum creatinine levels should be closely monitored in these patients.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Paediatric population</em></p><p>The safety and efficacy of PREVYMIS in patients below 18 years of age have not been established. No data are available (see section 5.1).</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For intravenous use only.</p><p>&nbsp;</p><p>PREVYMIS concentrate for solution for infusion requires dilution (see section 6.6) prior to administration.</p><p>&nbsp;</p><p>PREVYMIS diluted solution must be administered through a sterile 0.2&nbsp;micron or 0.22&nbsp;micron polyethersulfone (PES) in-line filter. Do not administer the diluted solution through a filter other than a sterile 0.2&nbsp;micron or 0.22&nbsp;micron PES in-line filter.</p><p>&nbsp;</p><p>PREVYMIS should be administered as an intravenous&nbsp; infusion only. PREVYMIS should not be administered as an intravenous push or bolus.</p><p>&nbsp;</p><p>After dilution, PREVYMIS should be administered by intravenous infusion via peripheral or central venous catheter using a total time of approximately 60 minutes. The entire contents of the intravenousbag should be administered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant administration with pimozide (see sections 4.4 and 4.5).
Concomitant administration with ergot alkaloids (see sections 4.4 and 4.5).
Concomitant administration with St. John’s wort (Hypericum perforatum) (see section 4.5).
When letermovir is combined with cyclosporine:
Concomitant use of dabigatran, atorvastatin, simvastatin, rosuvastatin or pitavastatin is contraindicated (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Monitoring of CMV DNA</u><u> in HSCT recipients</u></p><p>&nbsp;</p><p>In a Phase 3 trial (P001), the safety and efficacy of letermovir has been established in HSCT patients with a negative CMV DNA test result prior to initiation of prophylaxis. CMV DNA was monitored on a weekly basis until post-transplant Week 14, and subsequently every two weeks until Week 24. In cases of clinically significant CMV DNAemia or disease, letermovir prophylaxis was stopped and standard-of-care pre-emptive therapy (PET) or treatment was initiated. In patients in whom letermovir prophylaxis was initiated and the baseline CMV DNA test was subsequently found to be positive, prophylaxis could be continued if PET criteria had not been met (see section 5.1).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Risk of adverse reactions or reduced therapeutic effect due to medicinal product interactions</u></p><p>&nbsp;</p><p>The concomitant use of PREVYMIS and certain medicinal products may result in known or potentially significant medicinal product interactions, some of which may lead to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; possible clinically significant adverse reactions from greater exposure of concomitant medicinal products or letermovir.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; significant decrease of concomitant medicinal product plasma concentrations which may lead to reduced therapeutic effect of the concomitant medicinal product.</p><p>See Table 1 for steps to prevent or manage these known or potentially significant medicinal product interactions, including dosing recommendations (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Drug interactions</u></p><p>&nbsp;</p><p>PREVYMIS should be used with caution with medicinal products that are CYP3A substrates with narrow therapeutic ranges (e.g., alfentanil, fentanyl, and quinidine) as co-administration may result in increases in the plasma concentrations of CYP3A substrates. Close monitoring and/or dose adjustment of co-administered CYP3A substrates is recommended (see section 4.5).</p><p>Increased monitoring of cyclosporine, tacrolimus, sirolimus is generally recommended the first 2 weeks after initiating and ending letermovir (see section 4.5) as well as after changing route of administration of letermovir.</p><p>&nbsp;</p><p>Letermovir is a moderate inducer of enzymes and transporters. Induction may give rise to reduced plasma concentrations of some metabolised and transported medicinal products (see section 4.5). Therapeutic drug monitoring (TDM) is therefore recommended for voriconazole.</p><p>Concomitant use of dabigatran should be avoided due to risk of reduced dabigatran efficacy.</p><p>&nbsp;</p><p>Letermovir may increase the plasma concentrations of medicinal products transported by OATP1B1/3 such as many of the statins (see section 4.5 and Table 1).</p><p>&nbsp;</p><p><u>Administration through a sterile 0.2 or 0.22</u><u>&nbsp;micron PES in-line filter</u></p><p>&nbsp;</p><p>PREVYMIS concentrate for solution for infusion may contain a few product-related small translucent or white particles. Administration of PREVYMIS diluted solution always requires the use of a sterile 0.2&nbsp;micron or 0.22&nbsp;micron PES in-line filter, regardless of whether these product-related particles are visible in the vial or diluted solution (see sections 4.2 and 6.6).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Excipients</u></p><p>&nbsp;</p><p>Sodium</p><p>&nbsp;</p><p>This medicinal product contains 23&nbsp;mg (or 1&nbsp;mmol) sodium per 240&nbsp;mg vial, equivalent to 1.15% of the WHO recommended maximum daily intake of 2 g sodium for an adult. This should be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p><p>This medicinal product contains 46&nbsp;mg (or 2&nbsp;mmol) sodium per 480&nbsp;mg vial, equivalent to 2.30% of the WHO recommended maximum daily intake of 2 g sodium for an adult. This should be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p><p>Cyclodextrin</p><p>&nbsp;</p><p>This medicinal product contains 1800&nbsp;mg hydroxypropylbetadex (cyclodextrin) per 12&nbsp;mL vial (240&nbsp;mg dose).</p><p>&nbsp;</p><p>This medicinal product contains 3600&nbsp;mg hydroxypropylbetadex (cyclodextrin) per 24&nbsp;mL vial (480&nbsp;mg dose)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General information about differences in exposure between different letermovir treatment regimens</u><u> </u></p><p>&nbsp;</p><p>-The estimated letermovir plasma exposure is different depending on the dose regimen used (see table in section 5.2). Therefore, the clinical consequences of drug interactions for letermovir will be dependent on which letermovir regimen is used and whether or not letermovir is combined with cyclosporine.</p><p>-The combination of cyclosporine and letermovir may lead to more marked or additional effects on concomitant medicinal products as compared to letermovir alone (see Table 1).</p><p>&nbsp;</p><p><u>Effect</u><u> of other medicinal products on letermovir</u></p><p>&nbsp;</p><p>The elimination pathways of letermovir <em>in vivo</em> are biliary excretion and glucuronidation. The relative importance of these pathways is unknown. Both elimination pathways involve active uptake into the hepatocyte through the hepatic uptake transporters OATP1B1/ 3. After uptake, glucuronidation of letermovir is mediated by UGT1A1 and 3. Letermovir also appears to be subject to P-gp and BCRP mediated efflux in the liver and intestine (see section 5.2).</p><p>&nbsp;</p><p><u>Inducers of drug metabolising enzymes or transporters</u></p><p>&nbsp;</p><p>Co-administration of PREVYMIS (with or without cyclosporine) with strong and moderate inducers of transporters (e.g., P-gp) and/or enzymes (e.g., UGTs) is not recommended, as it may lead to subtherapeutic letermovir exposure (see Table 1).&nbsp;</p><p>-Examples of strong inducers include rifampicin, phenytoin, carbamazepine, St. John&rsquo;s wort (<em>Hypericum perforatum</em>), rifabutin and phenobarbital.</p><p>-Examples of moderate inducers include thioridazine, modafinil, ritonavir, lopinavir, efavirenz and etravirine.</p><p>&nbsp;</p><p>Rifampicin co-administration resulted in an initial increase in letermovir plasma concentrations (due to OATP1B1/3 and/or P-gp inhibition) that is not clinically relevant, followed by clinically relevant decreases in letermovir plasma concentrations (due to induction of P-gp/UGT) with continued rifampicin co-administration (see Table 1).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Additional effects of other products on letermovir relevant when combined with cyclosporine</u></p><p><u>&nbsp;</u></p><p><em>Inhibitors of OATP1B1 or 3</em><em> </em></p><p>Co-administration of PREVYMIS with medicinal products that are inhibitors of OATP1B1/3 transporters may result in increased letermovir plasma concentrations. If PREVYMIS is co-administered with cyclosporine (a potent OATP1B1/3 inhibitor), the recommended dose of PREVYMIS is 240&nbsp;mg once daily (see Table 1 and sections 4.2 and 5.2). Caution is advised if other OATP1B1/3 inhibitors are added to letermovir combined with cyclosporine.</p><p>-Examples of OATP1B1 inhibitors include gemfibrozil, erythromycin, clarithromycin, and several protease inhibitors (atazanavir, simeprevir).</p><p><u>&nbsp;</u></p><p><em>Inhibitors of P-gp/BCRP</em></p><p><em>In vitro</em> results indicate that letermovir is a substrate of P-gp/BCRP. Changes in letermovir plasma concentrations due to inhibition of P-gp/BCRP by itraconazole were not clinically relevant.</p><p>&nbsp;</p><p><u>Effect of letermovir on other medicinal products</u></p><p><u>&nbsp;</u></p><p><em>Medicinal products mainly eliminated through metabolism or influenced by active transport </em></p><p>Letermovir is a general inducer<em> in vivo </em>of enzymes and transporters. Unless a particular enzyme or transporter is also inhibited (see below) induction can be expected. Therefore, letermovir may potentially lead to decreased plasma exposure and possibly reduced efficacy of co-administered medicinal products that are mainly eliminated through metabolism or by active transport.</p><p>The size of the induction effect is dependent on letermovir route of administration and whether cyclosporine is concomitantly used. &nbsp;</p><p>The full induction effect can be expected after 10-14 days of letermovir treatment. The time needed to reach steady state of a specific affected medicinal product will also influence the time needed to reach full effect on the plasma concentrations.</p><p>&nbsp;</p><p><em>In vitro</em>, letermovir is an inhibitor of CYP3A, CYP2C8, CYP2B6, BCRP, UGT1A1, OATP2B1, and OAT3 at <em>in vivo</em> relevant concentrations. <em>In vivo</em> studies are available investigating the net effect on CYP3A4, P-gp, OATP1B1/3 additionally on CYP2C19. The net effect <em>in vivo</em> on the other listed enzymes and transporters is not known. Detailed information is presented below.</p><p>It is unknown whether letermovir may affect the exposure of piperacillin/tazobactam, amphotericine B and micafungin. The potential interaction between letermovir and these medicinal products have not been investigated. There is a theoretical risk of reduced exposure due to induction but the size of the effect and thus clinical relevance is presently unknown.</p><p>&nbsp;</p><p><em>Medicinal products metabolised by CYP3A</em></p><p>Letermovir is a moderate inhibitor of CYP3A <em>in vivo</em>. Co-administration of PREVYMIS with oral midazolam (a CYP3A substrate) results in 2-3-fold increased midazolam plasma concentrations. Co-administration of PREVYMIS may result in clinically relevant increases in the plasma concentrations of co-administered CYP3A substrates (see sections 4.3, 4.4, and 5.2).</p><p>-Examples of such medicinal products include certain immunosuppressants (e.g., cyclosporine, tacrolimus, sirolimus), HMG-CoA reductase inhibitors, and amiodarone (see Table 1). Pimozide and ergot alkaloids are contraindicated (see section 4.3).</p><p>The size of the CYP3A inhibitory effect is dependent on letermovir route of administration and whether cyclosporine is concomitantly used.</p><p>Due to time dependent inhibition and simultaneous induction the net enzyme inhibitory effect may not be reached until after 10-14 days. The time needed to reach steady state of a specific affected medicinal product will also influence the time needed to reach full effect on the plasma concentrations. When ending treatment, it takes 10-14 days for the inhibitory effect to disappear. If monitoring is applied, this is recommended the first 2 weeks after initiating and ending letermovir (see section 4.4) as well as after changing route of letermovir administration.</p><p>&nbsp;</p><p><em>Medicinal products transported by OATP1B1/3</em></p><p>Letermovir is an inhibitor of OATP1B1/3 transporters<em>.</em> Administration of PREVYMIS may result in a clinically relevant increase in plasma concentrations of co-administered medicinal products that are OATP1B1/3 substrates.</p><p>-Examples of such medicinal products include HMG-CoA reductase inhibitors, fexofenadine, repaglinide and glyburide (see Table 1). Comparing letermovir regimen administered without cyclosporine, the effect is more marked after intravenous than oral letermovir.</p><p>The magnitude of the OATP1B1/3 inhibition on co-administered medicinal products is likely greater when PREVYMIS is co-administered with cyclosporine (a potent OATP1B1/3 inhibitor). This needs to be considered when the letermovir regimen is changed during treatment with an OATP1B1/3 substrate.</p><p><em>&nbsp;</em></p><p><em>Medicinal products metabolised by CYP2C9 and/or CYP2C19</em></p><p>Co-administration of PREVYMIS with voriconazole (a CYP2C19 substrate) results in significantly decreased voriconazole plasma concentrations, indicating that letermovir is an inducer of CYP2C19. CYP2C9 is likely also induced. Letermovir has the potential to decrease the exposure of CYP2C9 and/or CYP2C19 substrates potentially resulting in subtherapeutic levels.</p><p>-Examples of such medicinal products include warfarin, voriconazole, diazepam, lansoprazole, omeprazole, esomeprazole, pantoprazole, tilidine, tolbutamide (see Table 1).</p><p>The effect is expected to be less pronounced for oral letermovir without cyclosporine, than intravenous letermovir with or without cyclosporine, or oral letermovir with cyclosporine. This needs to be considered when the letermovir regimen is changed during treatment with a CYP2C9 or CYP2C19 substrate. See also general information on induction above regarding time courses of the interaction.</p><p><em>&nbsp;</em></p><p><em>Medicinal products metabolised by CYP2C8</em></p><p>Letermovir inhibits CYP2C8 <em>in vitro</em> but may also induce CYP2C8 based on its induction potential. The net effect <em>in vivo </em>is unknown.</p><p>-An example of a medicinal product which is mainly eliminated by CYP2C8 is repaglinide (see Table&nbsp;1). Concomitant use of repaglinide and letermovir with or without cyclosporine is not recommended.</p><p>&nbsp;</p><p><em>Medicinal products transported by P-gp in the intestine</em></p><p>Letermovir is an inducer of intestinal P-gp. Administration of PREVYMIS may result in a clinically relevant decrease in plasma concentrations of co-administered medicinal products that are significantly transported by P-gp in the intestine such as dabigatran and sofosbuvir.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Medicinal products metabolised by CYP2B6, UGT1A1 or transported by BCRP or OATP2B1 </em></p><p>Letermovir is a general inducer<em> in viv</em>o but has also been observed to inhibit CYP2B6, UGT1A1, BCRP, and OATP2B1 <em>in vitro</em>. The net effect <em>in vivo</em> is unknown. Therefore, the plasma concentrations of medicinal products that are substrates of these enzymes or transporters may increase or decrease when co-administered with letermovir. Additional monitoring may be recommended; refer to the prescribing information for such medicinal products.</p><p>-Examples of medicinal products that are metabolised by CYP2B6 include bupropion.</p><p>-Examples of medicinal products metabolised by UGT1A1 are raltegravir and dolutegravir.</p><p>-Examples of medicinal products transported by BCRP include rosuvastatin and sulfasalazine.</p><p>-An example of a medicinal product transported by OATP2B1 is celiprolol.</p><p>&nbsp;</p><p><em>Medicinal products transported by the renal transporter OAT3</em></p><p><em>In vitro</em> data indicate that letermovir is an inhibitor of OAT3; therefore, letermovir may be an OAT3 inhibitor <em>in vivo</em>. Plasma concentrations of medicinal products transported by OAT3 may be increased.</p><p>-Examples of medicinal products transported by OAT3 includes ciprofloxacin, tenofovir, imipenem, and cilastin.</p><p>&nbsp;</p><p><u>General information</u></p><p>&nbsp;</p><p>If dose adjustments of concomitant medicinal products are made due to treatment with PREVYMIS, doses should be readjusted after treatment with PREVYMIS is completed. A dose adjustment may also be needed when changing route of administration or immunosuppressant.</p><p>&nbsp;</p><p>Table 1 provides a listing of established or potentially clinically significant medicinal product interactions. The medicinal product interactions described are based on studies conducted with PREVYMIS or are predicted medicinal product interactions that may occur with PREVYMIS (see sections 4.3, 4.4, 5.1, and 5.2).</p><p>&nbsp;</p><p><strong>Table 1: Interactions and dose recommendations with other medicinal products. Note that the table is not extensive but provides examples of clinically relevant interactions. See also the general text on DDIs above.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Unless otherwise specified, interaction studies have been performed with oral letermovir without cyclosporine. Please note that the interaction potential and clinical consequences may be different depending on whether letermovir is administered orally or </strong>intravenous<strong>, and whether cyclosporine is concomitantly used. When changing the route of administration, or if changing immunosuppressant, the recommendation concerning co-administration should be revisited. </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:102%"><thead><tr><td style="vertical-align:top"><p><strong>Concomitant medicinal product </strong></p></td><td style="vertical-align:top"><p><strong>Effect on concentration</strong><sup>&dagger;</sup><strong> </strong><strong>Mean ratio (90 % confidence interval) for AUC, C<sub>max</sub></strong><strong> (likely mechanism of action)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning co-administration with PREVYMIS</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Antibiotics</strong></p></td></tr><tr><td style="vertical-align:top"><p>nafcillin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Nafcillin may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and nafcillin is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antifungals</strong></p></td></tr><tr><td style="vertical-align:top"><p>fluconazole</p><p>(400&nbsp;mg single dose)/letermovir (480&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>&harr; fluconazole</p><p>AUC 1.03 (0.99, 1.08)</p><p>C<sub>max</sub> 0.95 (0.92, 0.99)</p><p>&harr; letermovir</p><p>AUC 1.11 (1.01, 1.23)</p><p>C<sub>max </sub>1.06 (0.93, 1.21)</p><p>&nbsp;</p><p>Interaction at steady state not studied.</p><p>Expected;</p><p>&harr; fluconazole</p><p>&harr; letermovir</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>itraconazole</p><p>(200&nbsp;mg once daily PO)/letermovir (480&nbsp;mg once daily PO)</p></td><td style="vertical-align:top"><p>&harr; itraconazole</p><p>AUC 0.76 (0.71, 0.81)</p><p>C<sub>max</sub> 0.84 (0.76, 0.92)</p><p>&nbsp;</p><p>&harr; letermovir</p><p>AUC 1.33 (1.17, 1.51)</p><p>C<sub>max</sub> 1.21 (1.05, 1.39)</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p></td></tr><tr><td style="vertical-align:top"><p>posaconazole<sup>&Dagger;</sup></p><p>(300&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&harr; posaconazole</p><p>AUC 0.98 (0.82, 1.17)</p><p>C<sub>max</sub> 1.11 (0.95, 1.29)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>voriconazole<sup>&Dagger;</sup></p><p>(200&nbsp;mg twice daily)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&darr; voriconazole</p><p>AUC 0.56 (0.51, 0.62)</p><p>C<sub>max</sub> 0.61 (0.53, 0.71)</p><p>&nbsp;</p><p>(CYP2C9/19 induction)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>If concomitant administration is necessary, TDM for voriconazole is recommended the first 2 weeks after initiating or ending letermovir, as well as after changing route of administration of letermovir or immunosuppressant.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antimycobacterials</strong></p></td></tr><tr><td style="vertical-align:top"><p>rifabutin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Rifabutin may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and rifabutin is not recommended.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rifampicin</p></td><td rowspan="5"><p>Multiple dose rifampicin decreases plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and rifampicin is not recommended.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>(600&nbsp;mg single dose PO)/ letermovir (480&nbsp;mg single dose PO)</p></td><td style="vertical-align:top"><p>&harr; letermovir</p><p>AUC 2.03 (1.84, 2.26)</p><p>C<sub>max</sub> 1.59 (1.46, 1.74)</p><p>C<sub>24</sub> 2.01 (1.59, 2.54)</p><p>&nbsp;</p><p>(OATP1B1/3 and/or P-gp inhibition)</p></td></tr><tr><td style="vertical-align:top"><p>(600&nbsp;mg single dose intravenous)/ letermovir (480&nbsp;mg single dose PO)</p></td><td style="vertical-align:top"><p>&harr; letermovir</p><p>AUC 1.58 (1.38, 1.81)</p><p>C<sub>max</sub> 1.37 (1.16, 1.61)</p><p>C<sub>24 </sub>0.78 (0.65, 0.93)</p><p>&nbsp;</p><p>(OATP1B1/3 and/or P-gp inhibition)</p></td></tr><tr><td style="vertical-align:top"><p>(600&nbsp;mg once daily PO)/ letermovir (480&nbsp;mg once daily PO)</p></td><td style="vertical-align:top"><p>&darr; letermovir</p><p>AUC 0.81 (0.67, 0.98)</p><p>C<sub>max</sub> 1.01 (0.79, 1.28)</p><p>C<sub>24 </sub>0.14 (0.11, 0.19)</p><p>&nbsp;</p><p>(Sum of OATP1B1/3 and/or P-gp inhibition and P-gp/UGT induction)</p></td></tr><tr><td style="vertical-align:top"><p>(600&nbsp;mg once daily PO (24 hours after rifampicin))<sup>&sect;</sup>/ letermovir (480&nbsp;mg once daily PO)</p></td><td style="vertical-align:top"><p>&darr; letermovir</p><p>AUC 0.15 (0.13, 0.17)</p><p>C<sub>max</sub> 0.27 (0.22, 0.31)</p><p>C<sub>24 </sub>0.09(0.06, 0.12)</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antipsychotics</strong></p></td></tr><tr><td style="vertical-align:top"><p>thioridazine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Thioridazine may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and thioridazine is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Endothelin antagonists</strong></p></td></tr><tr><td style="vertical-align:top"><p>bosentan</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Bosentan may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and bosentan is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antivirals</strong></p></td></tr><tr><td style="vertical-align:top"><p>acyclovir<sup>&Dagger;</sup></p><p>(400&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&harr; acyclovir</p><p>AUC 1.02 (0.87, 1.2)</p><p>C<sub>max</sub> 0.82 (0.71, 0.93)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>valacyclovir</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&harr; valacyclovir</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Herbal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>St. John&rsquo;s wort (<em>Hypericum perforatum</em>)</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>St. John&rsquo;s wort may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and St. John&rsquo;s wort is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HIV medicinal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>efavirenz</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>(P-gp/UGT induction)</p><p>&nbsp;</p><p>&uarr; or &darr; efavirenz</p><p>(CYP2B6 inhibition or induction)</p></td><td style="vertical-align:top"><p>Efavirenz may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and efavirenz is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>etravirine, nevirapine, ritonavir, lopinavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>These antivirals may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS with these antivirals is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HMG-CoA reductase inhibitors</strong></p></td></tr><tr><td style="vertical-align:top"><p>atorvastatin<sup>&Dagger;</sup></p><p>(20&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; atorvastatin</p><p>AUC 3.29 (2.84, 3.82)</p><p>C<sub>max</sub> 2.17 (1.76, 2.67)</p><p>&nbsp;</p><p>(CYP3A, OATP1B1/3 inhibition)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Statin-associated adverse events such as myopathy should be closely monitored. The dose of atorvastatin should not exceed 20&nbsp;mg daily when co-administered with PREVYMIS<sup>#</sup>.</p><p>&nbsp;</p><p>Although not studied, when PREVYMIS is co-administered with cyclosporine, the magnitude of the increase in atorvastatin plasma concentrations is expected to be greater than with PREVYMIS alone.</p><p>When PREVYMIS is co-administered with cyclosporine, atorvastatin is contraindicated.</p></td></tr><tr><td style="vertical-align:top"><p>simvastatin, pitavastatin,</p><p>rosuvastatin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; HMG-CoA reductase inhibitors</p><p>&nbsp;</p><p>(CYP3A, OATP1B1/3 inhibition)</p></td><td style="vertical-align:top"><p>Letermovir may substantially increase plasma concentrations of these statins. Concomitant use is not recommended with PREVYMIS alone.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, use of these statins is contraindicated.</p></td></tr><tr><td style="vertical-align:top"><p>fluvastatin, pravastatin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; HMG-CoA reductase inhibitors</p><p>&nbsp;</p><p>(OATP1B1/3 and/or BCRP inhibition)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letermovir may increase statin plasma concentrations.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with these statins, a statin dose reduction may be necessary<sup>#</sup>. Statin-associated adverse events such as myopathy should be closely monitored.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, pravastatin is not recommended while for fluvastatin, a dose reduction may be necessary<sup>#</sup>. Statin-associated adverse events such as myopathy should be closely monitored.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Immunosuppressants</strong></p></td></tr><tr><td style="vertical-align:top"><p>cyclosporine</p><p>(50&nbsp;mg single dose)/ letermovir (240&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; cyclosporine</p><p>AUC 1.66 (1.51, 1.82)</p><p>C<sub>max</sub> 1.08 (0.97, 1.19)</p><p>(CYP3A inhibition)</p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>If PREVYMIS is co-administered with cyclosporine, the dose of PREVYMIS should be decreased to 240&nbsp;mg once daily (see sections 4.2 and 5.1).</p><p>&nbsp;</p><p>Frequent monitoring of cyclosporine whole blood concentrations should be performed during treatment, when changing PREVYMIS administration route, and at discontinuation of PREVYMIS and the dose of cyclosporine adjusted accordingly<sup>#</sup>.<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>cyclosporine</p><p>(200&nbsp;mg single dose)/ letermovir (240&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; letermovir</p><p>AUC 2.11 (1.97, 2.26)</p><p>C<sub>max</sub> 1.48 (1.33, 1.65)</p><p>&nbsp;</p><p>(OATP1B1/3 inhibition)</p></td></tr><tr><td style="vertical-align:top"><p>mycophenolate mofetil</p><p>(1 g single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&harr;mycophenolic acid</p><p>AUC 1.08 (0.97, 1.20)</p><p>C<sub>max</sub> 0.96 (0.82, 1.12)</p><p>&nbsp;</p><p>&harr; letermovir</p><p>AUC 1.18 (1.04, 1.32)</p><p>C<sub>max</sub> 1.11 (0.92, 1.34)</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>sirolimus<sup>&Dagger;</sup></p><p>(2&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; sirolimus</p><p>AUC 3.40 (3.01, 3.85)</p><p>C<sub>max</sub> 2.76 (2.48, 3.06)</p><p>&nbsp;</p><p>(CYP3A inhibition)</p><p>&nbsp;</p><p>Interaction not studied.</p><p>Expected:</p><p>&harr; letermovir</p></td><td style="vertical-align:top"><p>Frequent monitoring of sirolimus whole blood concentrations should be performed during treatment, when changing PREVYMIS administration route, and at discontinuation of PREVYMIS and the dose of sirolimus adjusted accordingly<sup>#</sup>.</p><p>Frequent monitoring of sirolimus concentrations is recommended at initiation or discontinuation of cyclosporine co-administration with PREVYMIS.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, also refer to the sirolimus prescribing information for specific dosing recommendations for use of sirolimus with cyclosporine.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, the magnitude of the increase in concentrations of sirolimus may be greater than with PREVYMIS alone.</p></td></tr><tr><td style="vertical-align:top"><p>tacrolimus</p><p>(5&nbsp;mg single dose)/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&uarr; tacrolimus</p><p>AUC 2.42 (2.04, 2.88)</p><p>C<sub>max</sub> 1.57 (1.32, 1.86)</p><p>(CYP3A inhibition)</p></td><td rowspan="2" style="vertical-align:top"><p>Frequent monitoring of tacrolimus whole blood concentrations should be performed during treatment, when changing PREVYMIS administration route, and at discontinuation of PREVYMIS and the dose of tacrolimus adjusted accordingly<sup>#</sup>.<sup> </sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>tacrolimus</p><p>(5&nbsp;mg single dose)/ letermovir (80&nbsp;mg twice daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&harr; letermovir</p><p>AUC 1.02 (0.97, 1.07)</p><p>C<sub>max</sub> 0.92 (0.84, 1.00)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Oral contraceptives</strong></p></td></tr><tr><td style="vertical-align:top"><p>ethinylestradiol (EE) (0.03&nbsp;mg)/ levonorgestrel (LNG)<sup>&Dagger;</sup></p><p>(0.15&nbsp;mg) single dose/ letermovir (480&nbsp;mg daily)</p></td><td style="vertical-align:top"><p>&harr; EE</p><p>AUC 1.42 (1.32, 1.52)</p><p>C<sub>max</sub> 0.89 (0.83, 0.96)</p><p>&nbsp;</p><p>&harr; LNG</p><p>AUC 1.36 (1.30, 1.43)</p><p>C<sub>max</sub> 0.95 (0.86, 1.04)</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Other systemically acting oral contraceptive steroids</p></td><td style="vertical-align:top"><p>Risk of &darr; contraceptive steroids</p></td><td style="vertical-align:top"><p>Letermovir may reduce plasma concentrations of other oral contraceptive steroids thereby affecting their efficacy.</p><p>For adequate contraceptive effect to be ensured with an oral contraceptive, products containing EE and LNG should be chosen.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antidiabetic medicinal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>repaglinide</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; or &darr; repaglinide</p><p>&nbsp;</p><p>(CYP2C8 induction, CYP2C8 and OATP1B inhibition)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letermovir may increase or decrease the plasma concentrations of repaglinide. (The net effect is not known).</p><p>&nbsp;</p><p>Concomitant use is not recommended.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, the plasma concentrations of repaglinide is expected to increase due to the additional OATP1B inhibition by cyclosporine. Concomitant use is not recommended<sup>#</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>glyburide</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; glyburide</p><p>&nbsp;</p><p>(OATP1B1/3 inhibition CYP3A inhibition, CYP2C9 induction)</p></td><td style="vertical-align:top"><p>Letermovir may increase the plasma concentrations of glyburide.</p><p>&nbsp;</p><p>Frequent monitoring of glucose concentrations is recommended the first 2&nbsp;weeks after initiating or ending letermovir, as well as after changing route of administration of letermovir.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, refer also to the glyburide prescribing information for specific dosing recommendations.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Antiepileptic medicinal products (see also general text)</strong></p></td></tr><tr><td style="vertical-align:top"><p>carbamazepine,<br />phenobarbital</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Carbamazepine or phenobarbital may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and carbamazepine or phenobarbital is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>phenytoin</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p><p>&nbsp;</p><p>&darr; phenytoin</p><p>&nbsp;</p><p>(CYP2C9/19 induction)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Phenytoin may decrease plasma concentrations of letermovir.</p><p>&nbsp;</p><p>Letermovir may decrease the plasma concentrations of phenytoin.</p><p>&nbsp;</p><p>Co-administration of PREVYMIS and phenytoin is not recommended.</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Oral anticoagulants</strong></p></td></tr><tr><td style="vertical-align:top"><p>warfarin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; warfarin</p><p>&nbsp;</p><p>(CYP2C9 induction)</p></td><td style="vertical-align:top"><p>Letermovir may decrease the plasma concentrations of warfarin.</p><p>&nbsp;</p><p>Frequent monitoring of International Normalised Ratio (INR) should be performed when warfarin is co-administered with PREVYMIS treatment<sup>#</sup>. Monitoring is recommended the first 2&nbsp;weeks after initiating or ending letermovir, as well as after changing route of administration of letermovir or immunosuppressant.</p></td></tr><tr><td style="vertical-align:top"><p>dabigatran</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; dabigatran</p><p>&nbsp;</p><p>(intestinal P-gp induction)</p></td><td style="vertical-align:top"><p>Letermovir may decrease the plasma concentrations of dabigatran and may decrease efficacy of dabigatran. Concomitant use of dabigatran should be avoided due to the risk of reduced dabigatran efficacy.</p><p>&nbsp;</p><p>When PREVYMIS is co-administered with cyclosporine, dabigatran is contraindicated.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Sedatives</strong></p></td></tr><tr><td style="vertical-align:top"><p>midazolam</p><p>(1&nbsp;mg single dose intravenous)/ letermovir (240&nbsp;mg once daily PO)</p><p>&nbsp;</p><p>midazolam (2&nbsp;mg single dose PO) / letermovir (240&nbsp;mg once daily PO)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&uarr; midazolam</p><p>Intravenous:</p><p>AUC 1.47 (1.37, 1.58)</p><p>C<sub>max</sub> 1.05 (0.94, 1.17)</p><p>&nbsp;</p><p>PO:</p><p>AUC 2.25 (2.04, 2.48)</p><p>C<sub>max</sub> 1.72 (1.55, 1.92)</p><p>&nbsp;</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised during co-administration of PREVYMIS with midazolam. Dose adjustment of midazolam should be considered<sup>#</sup>. The increase in midazolam plasma concentration may be greater when oral midazolam is administered with letermovir at the clinical dose than with the dose studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Opioid agonists</strong></p></td></tr><tr><td style="vertical-align:top"><p>Examples: alfentanil, fentanyl</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; CYP3A metabolised opioids</p><p>&nbsp;</p><p>(CYP3A inhibition)</p></td><td style="vertical-align:top"><p>Frequent monitoring for adverse reactions related to these medicinal products is recommended during co-administration. Dose adjustment of CYP3A metabolised opioids may be needed<sup>#</sup> (see section 4.4).</p><p>Monitoring is also recommended if changing route of administration. When PREVYMIS is co-administered with cyclosporine, the magnitude of the increase in plasma concentrations of CYP3A metabolised opioids may be greater. Close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised during co-administration of PREVYMIS in combination with cyclosporine and alfentanil or fentanyl. Refer to the respective prescribing information (see section 4.4).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Anti-arrhythmic medicinal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>amiodarone</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; amiodarone</p><p>&nbsp;</p><p>(primarily CYP3A inhibition and CYP2C8 inhibition or induction)</p></td><td style="vertical-align:top"><p>Letermovir may increase the plasma concentrations of amiodarone.</p><p>&nbsp;</p><p>Frequent monitoring for adverse reactions related to amiodarone is recommended during co-administration. Monitoring of amiodarone concentrations should be performed regularly when amiodarone is co-administered with PREVYMIS<sup>#</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>quinidine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&uarr; quinidine</p><p>&nbsp;</p><p>(CYP3A inhibition)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letermovir may increase the plasma concentrations of quinidine.</p><p>&nbsp;</p><p>Close clinical monitoring should be exercised during administration of PREVYMIS with quinidine. Refer to the respective prescribing information<sup>#</sup>.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiovascular medicinal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>digoxin<sup>&Dagger;</sup></p><p>(0.5&nbsp;mg single dose)/ letermovir (240&nbsp;mg twice daily)</p></td><td style="vertical-align:top"><p>&harr; digoxin</p><p>AUC 0.88 (0.80, 0.96)</p><p>C<sub>max</sub> 0.75 (0.63, 0.89)</p><p>&nbsp;</p><p>(P-gp induction)</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Proton pump inhibitors</strong></p></td></tr><tr><td style="vertical-align:top"><p>omeprazole</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr;omeprazole</p><p>&nbsp;</p><p>(induction of CYP2C19)</p><p>&nbsp;</p><p>Interaction not studied.</p><p>Expected:</p><p>&harr; letermovir</p></td><td style="vertical-align:top"><p>Letermovir may decrease the plasma concentrations of CYP2C19 substrates.</p><p>&nbsp;</p><p>Clinical monitoring and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>pantoprazole</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; pantoprazole</p><p>&nbsp;</p><p>(likely due to induction of CYP2C19)</p><p>&nbsp;</p><p>Interaction not studied.</p><p>Expected:</p><p>&harr; letermovir</p></td><td style="vertical-align:top"><p>Letermovir may decrease the plasma concentrations of CYP2C19 substrates.</p><p>&nbsp;</p><p>Clinical monitoring and dose adjustment may be needed.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Wakefulness-promoting agents</strong></p></td></tr><tr><td style="vertical-align:top"><p>modafinil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>Expected:</p><p>&darr; letermovir</p><p>&nbsp;</p><p>(P-gp/UGT induction)</p></td><td style="vertical-align:top"><p>Modafinil may decrease plasma concentrations of letermovir.</p><p>Co-administration of PREVYMIS and modafinil is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*This table is not all inclusive.</p><p><strong><sup>&dagger;</sup></strong> &darr; =decrease, &uarr; =increase</p><p>&harr; =no clinically relevant change</p><p><sup>&Dagger; </sup>One-way interaction study assessing the effect of letermovir on the concomitant medicinal product.</p><p><sup>&sect; </sup>These data are the effect of rifampicin on letermovir 24 hours after final rifampicin dose.</p><p><sup>#</sup>Refer to the respective prescribing information.</p><p>&nbsp;</p></td></tr></tbody></table><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of letermovir in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>PREVYMIS is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether letermovir is excreted in human milk.</p><p>Available pharmacodynamic/toxicological data in animals have shown excretion of letermovir in milk (see section 5.3).</p><p>A risk to the newborns/infants cannot be excluded.</p><p>A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from PREVYMIS therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Fertility</u></p><p>&nbsp;</p><p>There were no effects on female fertility in rats. Irreversible testicular toxicity and impairment of fertility was observed in male rats, but not in male mice or male monkeys.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PREVYMIS may have minor influence on the ability to drive or use machines. Fatigue and vertigo have been reported in some patients during treatment with PREVYMIS, which may influence a patient&rsquo;s ability to drive and use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety assessment of PREVYMIS was based on three Phase 3 clinical trials.</p><p>&nbsp;</p><p><em>HSCT</em></p><p>In P001, 565 HSCT recipients received PREVYMIS or placebo through Week 14 post-transplant and were followed for safety through Week 24 post-transplant (see section 5.1). The most commonly reported adverse reactions occurring in at least 1% of subjects in the PREVYMIS group and at a frequency greater than placebo were: nausea (7.2%), diarrhoea (2.4%), and vomiting (1.9%). The most frequently reported adverse reactions that led to discontinuation of PREVYMIS were: nausea (1.6%), vomiting (0.8%), and abdominal pain (0.5%).</p><p>&nbsp;</p><p>In P040, 218 HSCT recipients received PREVYMIS or placebo from Week 14 (~100 days) through Week 28 (~200 days) post-HSCT and were followed for safety through Week 48 post-HSCT (see section 5.1). The adverse reactions reported were consistent with the safety profile of PREVYMIS as characterised in study P001.</p><p>&nbsp;</p><p><em>Kidney transplant</em></p><p>In P002, 292 kidney transplant recipients received PREVYMIS through Week 28 (~200 days) post-transplant (see section 5.1).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse reactions were identified in patients taking PREVYMIS in clinical trials. The adverse reactions are listed below by body system organ class and frequency. Frequencies are defined as follows: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) or very rare (&lt; 1/10,000).</p><p>&nbsp;</p><p><strong>Table 2: Adverse reactions identified with PREVYMIS</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>decreased appetite</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>dysgeusia, headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>nausea, diarrhoea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>alanine aminotransferase increased, aspartate aminotransferase increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>muscle spasms</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood creatinine increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>fatigue, oedema peripheral</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with human overdose with PREVYMIS. During Phase 1 clinical trials, 86 healthy subjects received doses ranging from 720&nbsp;mg/day to 1440&nbsp;mg/day of PREVYMIS for up to 14 days. The adverse reaction profile was similar to that of the clinical dose of 480&nbsp;mg/day. There is no specific antidote for overdose with PREVYMIS. In case of overdose, it is recommended that the patient be monitored for adverse reactions and appropriate symptomatic treatment instituted.</p><p>&nbsp;</p><p>It is unknown whether dialysis will result in meaningful removal of PREVYMIS from systemic circulation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, direct acting antivirals, ATC code: J05AX18</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Letermovir inhibits the CMV DNA terminase complex which is required for cleavage and packaging of viral progeny DNA. Letermovir affects the formation of proper unit length genomes and interferes with virion maturation.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Antiviral activity</u></p><p>&nbsp;</p><p>The median EC<sub>50 </sub>value of letermovir against a collection of clinical CMV isolates in a cell-culture model of infection was 2.1&nbsp;nM (range=0.7&nbsp;nM to 6.1&nbsp;nM, n=74).</p><p><u>&nbsp;</u></p><p><u>Viral resistance</u></p><p><em>&nbsp;</em></p><p><em>In cell culture</em></p><p>The CMV genes UL51, UL56, and UL89 encode subunits of CMV DNA terminase. CMV mutants with reduced susceptibility to letermovir have been confirmed in cell culture. EC<sub>50</sub> values for recombinant CMV mutants expressing the substitutions map to pUL51 (P91S), pUL56 (C25F, S229F, V231A, V231L, V236A, T244K, T244R, L254F, L257F, L257I, F261C, F261L, F261S, Y321C, L328V, M329T, A365S, N368D), and pUL89 (N320H, D344E) were 1.6- to &lt;10-fold higher than those for wild-type reference virus; these substitutions are not likely to be clinically relevant. EC<sub>50</sub> values for recombinant CMV mutants expressing pUL51 substitution A95V or pUL56 substitutions N232Y, V236L, V236M, E237D, E237G, L241P, K258E, C325F, C325R, C325W, C325Y, R369G, R369M, R369S and R369T were 10- to 9,300-fold higher than those for the wild-type reference virus; some of these substitutions have been observed in patients who have experienced prophylaxis failure in clinical trials (see below).</p><p><u>&nbsp;</u></p><p><em>In clinical </em><em>trials</em></p><p>In a Phase 2b trial evaluating letermovir doses of 60, 120, or 240&nbsp;mg/day or placebo for up to 84 days in 131 HSCT recipients, DNA sequence analysis of a select region of UL56 (amino acids 231 to 369) was performed on samples obtained from 12 letermovir-treated subjects who experienced prophylaxis failure and for whom samples were available for analysis. One subject (who received 60&nbsp;mg/day) had a letermovir resistant genotypic variant (GV) (V236M).</p><p>&nbsp;</p><p>In a Phase 3 trial (P001), DNA sequence analysis of the entire coding regions of UL56 and UL89 was performed on samples obtained from 40 letermovir-treated subjects in the FAS population who experienced prophylaxis failure and for whom samples were available for analysis. Two subjects had letermovir-resistant GVs detected, both with substitutions mapping to pUL56. One subject had the substitution V236M and the other subject had the substitution E237G. One additional subject, who had detectable CMV DNA at baseline (and was therefore not in the FAS population), had pUL56 substitutions, C325W and R369T, detected after discontinuing letermovir.</p><p>&nbsp;</p><p>In a Phase 3 trial (P040), DNA sequence analysis of the entire coding regions of UL51, UL56 and UL89 was performed on samples obtained from 32 subjects (regardless of treatment group) who experienced prophylaxis failure or who discontinued early with CMV viremia. There were no letermovir resistance-associated substitutions detected above the validated assay limit of 5%.</p><p>&nbsp;</p><p>In a Phase 3 trial (P002), DNA sequence analysis of the entire coding regions of UL51, UL56 and UL89 was performed on samples obtained from 52 letermovir-treated subjects who experienced CMV disease or who discontinued early with CMV viremia. There were no letermovir resistance-associated substitutions detected above the validated assay limit of 5%.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Cross-resistance</u></p><p>&nbsp;</p><p>Cross-resistance is not likely with medicinal products with a different mechanism of action. Letermovir is fully active against viral populations with substitutions conferring resistance to CMV DNA polymerase inhibitors (ganciclovir, cidofovir, and foscarnet). A panel of recombinant CMV strains with substitutions conferring resistance to letermovir was fully susceptible to cidofovir, foscarnet and ganciclovir with the exception of a recombinant strain with the pUL56 E237G substitution which confers a 2.1-fold reduction in ganciclovir susceptibility relative to wild-type.</p><p>&nbsp;</p><p><u>Cardiac electrophysiology</u></p><p>&nbsp;</p><p>The effect of letermovir on doses up to 960&nbsp;mg given intravenous on the QTc interval was evaluated in a randomised, single-dose, placebo- and active-controlled (moxifloxacin 400&nbsp;mg oral) 4-period crossover thorough QT trial in 38 healthy subjects. Letermovir does not prolong QTc to any clinically relevant extent following the 960&nbsp;mg intravenous dose with plasma concentrations approximately 2-fold higher than the 480&nbsp;mg intravenous dose.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>&nbsp;</em></p><p><em>Adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant</em></p><p><em>&nbsp;</em></p><p><em>P001: Prophylaxis through Week 14 (~100 days) post-HSCT</em></p><p>To evaluate letermovir prophylaxis as a preventive strategy for CMV infection or disease, the efficacy of letermovir was assessed in a multicentre, double-blind, placebo-controlled Phase 3 trial (P001) in adult CMV-seropositive recipients [R+] of an allogeneic HSCT. Subjects were randomised (2:1) to receive either letermovir at a dose of 480&nbsp;mg once daily adjusted to 240&nbsp;mg when co-administered with cyclosporine, or placebo. Randomisation was stratified by investigational site and risk (high vs. low) for CMV reactivation at the time of study entry. Letermovir was initiated after HSCT (Day 0-28 post-HSCT) and continued through Week 14 post-HSCT. Letermovir was administered either orally or intravenous; the dose of letermovir was the same regardless of the route of administration. Subjects were monitored through Week 24 post-HSCT for the primary efficacy endpoint with continued follow-up through Week 48 post-HSCT.</p><p>&nbsp;</p><p>Subjects received CMV DNA monitoring weekly until post-HSCT week 14 and then every two weeks until post-HSCT week 24, with initiation of standard-of-care CMV pre-emptive therapy if CMV DNAemia was considered clinically significant. Subjects had continued follow-up through Week 48 post-HSCT.</p><p>&nbsp;</p><p>Among the 565 treated subjects, 373 subjects received letermovir (including 99 subjects who received at least one intravenous dose) and 192 received placebo (including 48 subjects who received at least one intravenous dose). The median time to starting letermovir was 9 days after transplantation. Thirty-seven percent (37%) of subjects were engrafted at baseline. The median age was 54 years (range: 18 to 78 years); 56 (15.0%) subjects were 65 years of age or older: 58% were male; 82% were White; 10% were Asian; 2% were Black or African; and 7% were Hispanic or Latino. At baseline, 50% of subjects received a myeloablative regimen, 52% were receiving cyclosporine, and 42% were receiving tacrolimus. The most common primary reasons for transplant were acute myeloid leukaemia (38%), myeloblastic syndrome (15%), and lymphoma (13%). Twelve percent (12%) of subjects were positive for CMV DNA at baseline.</p><p>&nbsp;</p><p>At baseline, 31% of subjects were at high risk for reactivation as defined by one or more of the following criteria: Human Leucocyte Antigen (HLA)-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B or &ndash;DR, haploidentical donor; unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, -C and -DRB1; use of umbilical cord blood as stem cell source; use of <em>ex vivo</em> T-cell-depleted grafts; Grade 2 or greater Graft-Versus-Host Disease (GVHD), requiring systemic corticosteroids.</p><p>&nbsp;</p><p><em>Primary efficacy endpoint</em></p><p>The primary efficacy endpoint of clinically significant CMV infection in P001 was defined by the incidence of CMV DNAemia warranting anti-CMV pre-emptive therapy (PET) or the occurrence of CMV end-organ disease. The Non-Completer=Failure (NC=F) approach was used, where subjects who discontinued from the study prior to Week 24 post-HSCT or had a missing outcome at Week 24 post-HSCT were counted as failures.</p><p>Letermovir demonstrated superior efficacy over placebo in the analysis of the primary endpoint, as shown in Table 3. The estimated treatment difference of -23.5% was statistically significant (one-sided p‑value &lt;0.0001).</p><p>&nbsp;</p><p><strong>Table 3</strong>: <strong>P001: Efficacy results</strong> <strong>in HSCT recipients (NC=F Approach, FAS Population)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Letermovir</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(N=325)</p></td><td style="vertical-align:top"><p>(N=170)</p></td></tr><tr><td style="vertical-align:top"><p>Parameter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>n (%)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Primary efficacy endpoint</p><p>(Proportion of subjects who failed prophylaxis by Week 24)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>122 (37.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>103 (60.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Reasons for Failures<sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clinically significant CMV infection&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>57 (17.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>71 (41.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; CMV DNAemia warranting anti-CMV PET</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp; 52 (16.0)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp; 68 (40.0)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; CMV end-organ disease&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 5 (1.5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 3 (1.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued from study&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>56 (17.2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>27 (15.9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Missing outcome&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; 9 (2.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; 5 (2.9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Stratum-adjusted treatment difference (Letermovir-Placebo)<sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>-23.5 (-32.5, -14.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.0001&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>&dagger;</sup> The categories of failure are mutually exclusive and based on the hierarchy of categories in the order listed.</p><p><sup>&sect;</sup> 95% CIs and p-value for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (high or low risk). A 1-sided p-value &le;0.0249 was used for declaring statistical significance.</p><p>FAS=Full analysis set; FAS includes randomised subjects who received at least one dose of study medicine, and excludes subjects with detectable CMV DNA at baseline. Approach to handling missing values: Non-Completer=Failure (NC=F) approach. With NC=F approach, failure was defined as all subjects with clinically significant CMV infection or who prematurely discontinued from the study or had a missing outcome through Week 24 post-transplant visit window.</p><p>N=number of subjects in each treatment group.</p><p>n (%)=Number (percent) of subjects in each sub-category.</p><p>Note: The proportion of subjects with detectable CMV viral DNA on Day 1 that developed clinically significant CMV infection in the letermovir group was 64.6% (31/48) compared to 90.9% (20/22) in the placebo group through Week 24 post-HSCT. The estimated difference (95% CI for the difference) was -26.1% (-45.9%, -6.3%), with a nominal one-sided p-value &lt;0.0048.</p><p>&nbsp;</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p>Factors associated with CMV DNAemia after Week 14 post-HSCT among letermovir-treated subjects included high risk for CMV reactivation at baseline, GVHD, use of corticosteroids, and CMV negative donor serostatus.</p><p>&nbsp;</p><p><strong>Figure 1: P001: Kaplan-Meier plot of time to initiation of anti-CMV PET or onset of CMV end-organ disease through Week 24 post-transplant in HSCT recipients (FAS population)</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_872" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:445.5pt;height:383.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title="" croptop="7046f" cropbottom="11236f" cropleft="8435f" cropright="16678f"/>
</v:shape><![endif]--><img width="594" height="511" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p><strong><u>&nbsp;</u></strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>&nbsp;</u></strong></p><p>There were no differences in the incidence of or time to engraftment between the PREVYMIS and placebo groups.</p><p>&nbsp;</p><p>Efficacy consistently favoured letermovir across subgroups including low and high risk for CMV reactivation, conditioning regimens, and concomitant immunosuppressive regimens (see Figure 2).</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>Figure 2: P001: Forest plot of the proportion of subjects initiating anti-CMV PET or with CMV end-organ disease through Week 24 post-HSCT by selected subgroups (NC=F approach, FAS population)</strong></p><p><strong><u>&nbsp;</u></strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Canvas_x0020_824" o:spid="_x0000_s1026"
 editas="canvas" style='width:468pt;height:361.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="59436,45910" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
  width:59436;height:45910;visibility:visible;mso-wrap-style:square'>
  <v:fill o:detectmouseclick="t"/>
  <v:path o:connecttype="none"/>
 </v:shape><v:rect id="Rectangle_x0020_5" o:spid="_x0000_s1028" style='position:absolute;
  left:27051;top:36715;width:26949;height:7;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" strokeweight=".55pt"/>
 <v:line id="Line_x0020_6" o:spid="_x0000_s1029" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="29476,36722" to="29476,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_7" o:spid="_x0000_s1030" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="31934,36722" to="31934,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".55pt"/>
 <v:line id="Line_x0020_8" o:spid="_x0000_s1031" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="34378,36722" to="34378,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".55pt"/>
 <v:line id="Line_x0020_9" o:spid="_x0000_s1032" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="36836,36722" to="36836,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAl57cNwgAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Li8JA
EITvwv6HoRe86WSFVYkZRRZcFsGDD0RvbabzIJmekJnV+O8dQfBYVNVXVLLoTC2u1LrSsoKvYQSC
OLW65FzBYb8aTEE4j6yxtkwK7uRgMf/oJRhre+MtXXc+FwHCLkYFhfdNLKVLCzLohrYhDl5mW4M+
yDaXusVbgJtajqJoLA2WHBYKbOinoLTa/RsF1a8+ny+V7qrJ0eJ6c+f6lLFS/c9uOQPhqfPv8Kv9
pxV8w/NKuAFy/gAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAl57cNwgAAANoAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_10" o:spid="_x0000_s1033" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="39293,36722" to="39293,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".55pt"/>
 <v:line id="Line_x0020_11" o:spid="_x0000_s1034" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="41751,36722" to="41751,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_12" o:spid="_x0000_s1035" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="44208,36722" to="44208,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".55pt"/>
 <v:line id="Line_x0020_13" o:spid="_x0000_s1036" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="46672,36722" to="46672,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".55pt"/>
 <v:line id="Line_x0020_14" o:spid="_x0000_s1037" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="49117,36722" to="49117,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".55pt"/>
 <v:line id="Line_x0020_15" o:spid="_x0000_s1038" style='position:absolute;
  flip:y;visibility:visible;mso-wrap-style:square' from="51574,36722" to="51574,37420"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".55pt"/>
 <v:rect id="Rectangle_x0020_16" o:spid="_x0000_s1039" style='position:absolute;
  left:28581;top:38087;width:1657;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-70</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_17" o:spid="_x0000_s1040" style='position:absolute;
  left:31045;top:38087;width:1657;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBlN78BwgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/dagIx
FITvBd8hHME7zbpCK6tRRBBs6Y2rD3DYnP3B5GRJort9+6ZQ6OUwM98wu8NojXiRD51jBatlBoK4
crrjRsH9dl5sQISIrNE4JgXfFOCwn052WGg38JVeZWxEgnAoUEEbY19IGaqWLIal64mTVztvMSbp
G6k9Dglujcyz7E1a7DgttNjTqaXqUT6tAnkrz8OmND5zn3n9ZT4u15qcUvPZeNyCiDTG//Bf+6IV
vOdr+D2TjoDc/wAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBlN78BwgAAANwAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-60</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_18" o:spid="_x0000_s1041" style='position:absolute;
  left:33489;top:38087;width:1658;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-50</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_19" o:spid="_x0000_s1042" style='position:absolute;
  left:35947;top:38087;width:1657;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCFkoLuwgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/dagIx
FITvBd8hHME7zbpgK6tRRBBs6Y2rD3DYnP3B5GRJort9+6ZQ6OUwM98wu8NojXiRD51jBatlBoK4
crrjRsH9dl5sQISIrNE4JgXfFOCwn052WGg38JVeZWxEgnAoUEEbY19IGaqWLIal64mTVztvMSbp
G6k9Dglujcyz7E1a7DgttNjTqaXqUT6tAnkrz8OmND5zn3n9ZT4u15qcUvPZeNyCiDTG//Bf+6IV
vOdr+D2TjoDc/wAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCFkoLuwgAAANwAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-40</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_20" o:spid="_x0000_s1043" style='position:absolute;
  left:38404;top:38087;width:1658;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-30</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_21" o:spid="_x0000_s1044" style='position:absolute;
  left:40862;top:38087;width:1657;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-20</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_22" o:spid="_x0000_s1045" style='position:absolute;
  left:43319;top:38087;width:1658;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>-10</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_23" o:spid="_x0000_s1046" style='position:absolute;
  left:46323;top:38087;width:641;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>0</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_24" o:spid="_x0000_s1047" style='position:absolute;
  left:48418;top:38087;width:1277;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>10</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_25" o:spid="_x0000_s1048" style='position:absolute;
  left:50876;top:38087;width:1276;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt;font-family:
     "Arial",sans-serif;color:black'>20</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_26" o:spid="_x0000_s1049" style='position:absolute;
  left:17291;top:41148;width:28359;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='color:black'>Letermovir -
     Placebo Difference (%) and 95% C.I.</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_27" o:spid="_x0000_s1050" style='position:absolute;
  left:38677;top:3873;width:4407;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_28" o:spid="_x0000_s1051" style='position:absolute;
  left:38608;top:3562;width:152;height:781;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBXsV1rxwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9PawIx
FMTvBb9DeEJvNVur1W6NooLQi1D/HPT23LzuLm5e1iTq1k9vhEKPw8z8hhlNGlOJCzlfWlbw2klA
EGdWl5wr2G4WL0MQPiBrrCyTgl/yMBm3nkaYanvlFV3WIRcRwj5FBUUIdSqlzwoy6Du2Jo7ej3UG
Q5Qul9rhNcJNJbtJ8i4NlhwXCqxpXlB2XJ+NgtnHcHb67vHytjrsab87HPtdlyj13G6mnyACNeE/
/Nf+0goGbz14nIlHQI7vAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAFexXWvHAAAA3AAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_29" o:spid="_x0000_s1052" style='position:absolute;
  left:43014;top:3562;width:153;height:781;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_30" o:spid="_x0000_s1053" style='position:absolute;
  left:34994;top:7385;width:8008;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_31" o:spid="_x0000_s1054" style='position:absolute;
  left:34925;top:7073;width:152;height:788;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_32" o:spid="_x0000_s1055" style='position:absolute;
  left:42932;top:7073;width:152;height:788;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_33" o:spid="_x0000_s1056" style='position:absolute;
  left:38976;top:8547;width:5283;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_34" o:spid="_x0000_s1057" style='position:absolute;
  left:38906;top:8242;width:152;height:781;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_35" o:spid="_x0000_s1058" style='position:absolute;
  left:44189;top:8242;width:153;height:781;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_36" o:spid="_x0000_s1059" style='position:absolute;
  left:38169;top:12065;width:5309;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_37" o:spid="_x0000_s1060" style='position:absolute;
  left:38093;top:11753;width:159;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCAXrZixwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9PawIx
FMTvBb9DeEJvNVur1W6NooLQi1D/HPT23LzuLm5e1iTq1k9vhEKPw8z8hhlNGlOJCzlfWlbw2klA
EGdWl5wr2G4WL0MQPiBrrCyTgl/yMBm3nkaYanvlFV3WIRcRwj5FBUUIdSqlzwoy6Du2Jo7ej3UG
Q5Qul9rhNcJNJbtJ8i4NlhwXCqxpXlB2XJ+NgtnHcHb67vHytjrsab87HPtdlyj13G6mnyACNeE/
/Nf+0goGvTd4nIlHQI7vAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAIBetmLHAAAA3AAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_38" o:spid="_x0000_s1061" style='position:absolute;
  left:43402;top:11753;width:159;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAPty4WxwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9PawIx
FMTvhX6H8ARvNatsq65GqQXBS6H+OejtuXnuLm5etknUbT99IxQ8DjPzG2Y6b00truR8ZVlBv5eA
IM6trrhQsNsuX0YgfEDWWFsmBT/kYT57fppipu2N13TdhEJECPsMFZQhNJmUPi/JoO/Zhjh6J+sM
hihdIbXDW4SbWg6S5E0arDgulNjQR0n5eXMxChbj0eL7K+XP3/XxQIf98fw6cIlS3U77PgERqA2P
8H97pRUM0xTuZ+IRkLM/AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAA+3LhbHAAAA3AAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_39" o:spid="_x0000_s1062" style='position:absolute;
  left:35960;top:13239;width:8915;height:153;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_40" o:spid="_x0000_s1063" style='position:absolute;
  left:35890;top:12928;width:152;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCQKRX6xwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NawIx
FMTvBf+H8ARvNatYP1ajVEHopVA/Dnp7bp67i5uXbRJ1619vCoUeh5n5DTNbNKYSN3K+tKyg101A
EGdWl5wr2O/Wr2MQPiBrrCyTgh/ysJi3XmaYanvnDd22IRcRwj5FBUUIdSqlzwoy6Lu2Jo7e2TqD
IUqXS+3wHuGmkv0kGUqDJceFAmtaFZRdtlejYDkZL7+/Bvz52JyOdDycLm99lyjVaTfvUxCBmvAf
/mt/aAWjwRB+z8QjIOdPAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAJApFfrHAAAA3AAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_41" o:spid="_x0000_s1064" style='position:absolute;
  left:44805;top:12928;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_42" o:spid="_x0000_s1065" style='position:absolute;
  left:39985;top:16751;width:7684;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_43" o:spid="_x0000_s1066" style='position:absolute;
  left:39916;top:16440;width:152;height:787;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_44" o:spid="_x0000_s1067" style='position:absolute;
  left:47593;top:16440;width:159;height:787;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_45" o:spid="_x0000_s1068" style='position:absolute;
  left:30600;top:17913;width:11868;height:159;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_46" o:spid="_x0000_s1069" style='position:absolute;
  left:30530;top:17608;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_47" o:spid="_x0000_s1070" style='position:absolute;
  left:42392;top:17608;width:159;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_48" o:spid="_x0000_s1071" style='position:absolute;
  left:35591;top:19088;width:6922;height:158;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_49" o:spid="_x0000_s1072" style='position:absolute;
  left:35521;top:18783;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_50" o:spid="_x0000_s1073" style='position:absolute;
  left:42443;top:18783;width:152;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_51" o:spid="_x0000_s1074" style='position:absolute;
  left:38119;top:20256;width:12598;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_52" o:spid="_x0000_s1075" style='position:absolute;
  left:38049;top:19945;width:152;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_53" o:spid="_x0000_s1076" style='position:absolute;
  left:50647;top:19945;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_54" o:spid="_x0000_s1077" style='position:absolute;
  left:30695;top:23768;width:12415;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_55" o:spid="_x0000_s1078" style='position:absolute;
  left:30626;top:23456;width:152;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_56" o:spid="_x0000_s1079" style='position:absolute;
  left:43033;top:23456;width:159;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_57" o:spid="_x0000_s1080" style='position:absolute;
  left:39071;top:24942;width:4750;height:153;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_58" o:spid="_x0000_s1081" style='position:absolute;
  left:39001;top:24638;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_59" o:spid="_x0000_s1082" style='position:absolute;
  left:43751;top:24638;width:152;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_60" o:spid="_x0000_s1083" style='position:absolute;
  left:38334;top:28448;width:6389;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_61" o:spid="_x0000_s1084" style='position:absolute;
  left:38265;top:28136;width:152;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_62" o:spid="_x0000_s1085" style='position:absolute;
  left:44653;top:28136;width:152;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_63" o:spid="_x0000_s1086" style='position:absolute;
  left:37407;top:29622;width:8719;height:153;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_64" o:spid="_x0000_s1087" style='position:absolute;
  left:37338;top:29311;width:152;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQC+4OKowwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE+7bsIw
FN2R+g/WrcQGThHPNAaVSkgslYB2gO0S3yZR4uvUNpDy9Xio1PHovLNVZxpxJecrywpehgkI4tzq
igsFX5+bwRyED8gaG8uk4Jc8rJZPvQxTbW+8p+shFCKGsE9RQRlCm0rp85IM+qFtiSP3bZ3BEKEr
pHZ4i+GmkaMkmUqDFceGElt6LymvDxejYL2Yr392Y/64788nOh3P9WTkEqX6z93bK4hAXfgX/7m3
WsFsFufHM/EIyOUDAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAvuDiqMMAAADcAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_65" o:spid="_x0000_s1088" style='position:absolute;
  left:46050;top:29311;width:158;height:788;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_66" o:spid="_x0000_s1089" style='position:absolute;
  left:34048;top:30797;width:8928;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_67" o:spid="_x0000_s1090" style='position:absolute;
  left:33972;top:30486;width:159;height:787;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_68" o:spid="_x0000_s1091" style='position:absolute;
  left:42906;top:30486;width:153;height:787;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_69" o:spid="_x0000_s1092" style='position:absolute;
  left:36055;top:34296;width:5950;height:159;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_70" o:spid="_x0000_s1093" style='position:absolute;
  left:35979;top:33991;width:158;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_71" o:spid="_x0000_s1094" style='position:absolute;
  left:41929;top:33991;width:158;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_72" o:spid="_x0000_s1095" style='position:absolute;
  left:39344;top:35477;width:7055;height:152;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_73" o:spid="_x0000_s1096" style='position:absolute;
  left:39274;top:35166;width:153;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:rect id="Rectangle_x0020_74" o:spid="_x0000_s1097" style='position:absolute;
  left:46323;top:35166;width:159;height:781;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <v:shape id="Freeform_x0020_75" o:spid="_x0000_s1098" style='position:absolute;
  left:40519;top:3575;width:762;height:755;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r60,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_76" o:spid="_x0000_s1099" style='position:absolute;
  left:38620;top:7086;width:756;height:762;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="119,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r59,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_77" o:spid="_x0000_s1100" style='position:absolute;
  left:41230;top:8248;width:762;height:762;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAWYYgQxAAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pi8Iw
FMTvgt8hPGFvmrorbqlGkcWyHgTR9eDx0bz+wealNFG7fnojCB6HmfkNM192phZXal1lWcF4FIEg
zqyuuFBw/EuHMQjnkTXWlknBPzlYLvq9OSba3nhP14MvRICwS1BB6X2TSOmykgy6kW2Ig5fb1qAP
si2kbvEW4KaWn1E0lQYrDgslNvRTUnY+XIwCn/5uisnuTqstxynr0249znOlPgbdagbCU+ff4Vd7
oxV8x1/wPBOOgFw8AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhABZhiBDEAAAA3AAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_78" o:spid="_x0000_s1101" style='position:absolute;
  left:40436;top:11766;width:756;height:756;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAVMBs2xgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/RSsNA
FETfC/2H5Rb6ImYTKzXGbouWCn0RbPQDLtlrNpi9G7PbJvl7VxD6OMzMGWazG20rLtT7xrGCLElB
EFdON1wr+Px4vc1B+ICssXVMCibysNvOZxsstBv4RJcy1CJC2BeowITQFVL6ypBFn7iOOHpfrrcY
ouxrqXscIty28i5N19Jiw3HBYEd7Q9V3ebYK7EuZlebxcNOtjoe393zKfoapVWq5GJ+fQAQawzX8
3z5qBQ/5PfydiUdAbn8BAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAFTAbNsYAAADcAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" path="m60,r59,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_79" o:spid="_x0000_s1102" style='position:absolute;
  left:40043;top:12941;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD2xLX/xAAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pi8Iw
FMTvgt8hPGFvmrqsbqlGkcWyHgTR9eDx0bz+wealNFG7fnojCB6HmfkNM192phZXal1lWcF4FIEg
zqyuuFBw/EuHMQjnkTXWlknBPzlYLvq9OSba3nhP14MvRICwS1BB6X2TSOmykgy6kW2Ig5fb1qAP
si2kbvEW4KaWn1E0lQYrDgslNvRTUnY+XIwCn/5uiq/dnVZbjlPWp916nOdKfQy61QyEp86/w6/2
Riv4jifwPBOOgFw8AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAPbEtf/EAAAA3AAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_80" o:spid="_x0000_s1103" style='position:absolute;
  left:43465;top:16452;width:756;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r59,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_81" o:spid="_x0000_s1104" style='position:absolute;
  left:36163;top:17621;width:755;height:755;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m59,r60,59l59,119,,59,59,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_82" o:spid="_x0000_s1105" style='position:absolute;
  left:38665;top:18796;width:762;height:755;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m60,r60,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_83" o:spid="_x0000_s1106" style='position:absolute;
  left:44024;top:19958;width:756;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m59,r60,60l59,120,,60,59,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_84" o:spid="_x0000_s1107" style='position:absolute;
  left:36531;top:23469;width:756;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="119,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m59,r60,60l59,120,,60,59,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_85" o:spid="_x0000_s1108" style='position:absolute;
  left:41052;top:24644;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAMJiUhxgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvBb/D8gq91U2KtDZmIyINzUEIag8eH9mXPzT7NmRXTfvpu0LB4zAzv2HS9WR6caHRdZYVxPMI
BHFldceNgq9j/rwE4Tyyxt4yKfghB+ts9pBiou2V93Q5+EYECLsEFbTeD4mUrmrJoJvbgTh4tR0N
+iDHRuoRrwFuevkSRa/SYMdhocWBti1V34ezUeDzz6JZlL+02fEyZ30qP+K6VurpcdqsQHia/D38
3y60grf3GG5nwhGQ2R8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEADCYlIcYAAADcAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_86" o:spid="_x0000_s1109" style='position:absolute;
  left:41148;top:28149;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_87" o:spid="_x0000_s1110" style='position:absolute;
  left:41395;top:29324;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_88" o:spid="_x0000_s1111" style='position:absolute;
  left:38131;top:30499;width:762;height:762;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m60,r60,60l60,120,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_89" o:spid="_x0000_s1112" style='position:absolute;
  left:38639;top:34004;width:762;height:755;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m60,r60,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:shape id="Freeform_x0020_90" o:spid="_x0000_s1113" style='position:absolute;
  left:42475;top:35179;width:762;height:755;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' coordsize="120,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m60,r60,60l60,119,,60,60,xe" fillcolor="#0080ff" strokecolor="#0080ff"
  strokeweight="0">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="2147483646,0;2147483646,2147483646;2147483646,2147483646;0,2147483646;2147483646,0"
   o:connectangles="0,0,0,0,0"/>
 </v:shape><v:rect id="Rectangle_x0020_91" o:spid="_x0000_s1114" style='position:absolute;
  left:46634;top:1612;width:57;height:35110;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCYj8YCwwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/disIw
FITvF3yHcATvNFXBn2oqIggKLrurPsCxOf3R5qQ0UevbbxaEvRxm5htmuWpNJR7UuNKyguEgAkGc
Wl1yruB82vZnIJxH1lhZJgUvcrBKOh9LjLV98g89jj4XAcIuRgWF93UspUsLMugGtiYOXmYbgz7I
Jpe6wWeAm0qOomgiDZYcFgqsaVNQejvejQJHo8N+d7J0yfbmdbVj+d1+finV67brBQhPrf8Pv9s7
rWA6n8LfmXAEZPILAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAmI/GAsMAAADcAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" fillcolor="#0080ff" strokecolor="#0080ff" strokeweight=".55pt"/>
 <v:rect id="Rectangle_x0020_92" o:spid="_x0000_s1115" style='position:absolute;
  left:37274;top:39604;width:8934;height:1436;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" stroked="f"/>
 <v:rect id="Rectangle_x0020_93" o:spid="_x0000_s1116" style='position:absolute;
  left:37820;top:39738;width:7188;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:7.0pt;color:black'>Favors
     Letermovir</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_94" o:spid="_x0000_s1117" style='position:absolute;
  left:12280;top:34893;width:9691;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Tacrolimus
     (n=145, 69)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_95" o:spid="_x0000_s1118" style='position:absolute;
  left:47002;top:39604;width:7728;height:1436;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" stroked="f"/>
 <v:rect id="Rectangle_x0020_96" o:spid="_x0000_s1119" style='position:absolute;
  left:47548;top:39738;width:5804;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:7.0pt;color:black'>Favors
     Placebo</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_97" o:spid="_x0000_s1120" style='position:absolute;
  left:12280;top:29038;width:17253;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Reduced
     intensity conditioning (n=86, 48)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_98" o:spid="_x0000_s1121" style='position:absolute;
  left:12280;top:33718;width:11018;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Cyclosporin
     A (n=162, 90)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_99" o:spid="_x0000_s1122" style='position:absolute;
  left:9823;top:22009;width:8611;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQA4k0rYwgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/dagIx
FITvC32HcAq9q4lCZVmNIoJgS29cfYDD5uwPJidLkrrr25tCwcthZr5h1tvJWXGjEHvPGuYzBYK4
9qbnVsPlfPgoQMSEbNB6Jg13irDdvL6ssTR+5BPdqtSKDOFYooYupaGUMtYdOYwzPxBnr/HBYcoy
tNIEHDPcWblQaikd9pwXOhxo31F9rX6dBnmuDmNR2aD896L5sV/HU0Ne6/e3abcCkWhKz/B/+2g0
FOoT/s7kIyA3DwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQA4k0rYwgAAANwAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Haploidentical
     donor</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_100" o:spid="_x0000_s1123" style='position:absolute;
  left:12280;top:30213;width:12396;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Non-myeloablative
     (n=85, 37)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_101" o:spid="_x0000_s1124" style='position:absolute;
  left:9823;top:32550;width:12109;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Immunosuppressive
     Regimen</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_102" o:spid="_x0000_s1125" style='position:absolute;
  left:9823;top:26701;width:9290;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Conditioning
     Regimen</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_103" o:spid="_x0000_s1126" style='position:absolute;
  left:12280;top:27863;width:10929;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Myeloablative
     (n=154, 85)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_104" o:spid="_x0000_s1127" style='position:absolute;
  left:12280;top:24358;width:6814;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCtPX+dvwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/LisIw
FN0L/kO4A+40rYuhVKMMAwWV2VjnAy7N7YNJbkoSbf17sxBmeTjv/XG2RjzIh8GxgnyTgSBunB64
U/B7q9YFiBCRNRrHpOBJAY6H5WKPpXYTX+lRx06kEA4lKuhjHEspQ9OTxbBxI3HiWuctxgR9J7XH
KYVbI7dZ9iktDpwaehzpu6fmr75bBfJWV1NRG5+5y7b9MefTtSWn1Opj/tqBiDTHf/HbfdIKijzN
T2fSEZCHFwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAAAAAA
AAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAAAAAA
AAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCtPX+dvwAAANwAAAAPAAAAAAAA
AAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA8wIAAAAA
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>No
     (n=276, 153)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_105" o:spid="_x0000_s1128" style='position:absolute;
  left:12280;top:23183;width:6135;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDCcdoGwQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/disIw
FITvBd8hHGHvNK0XS+kaRQRBF2+s+wCH5vSHTU5KEm337Y0g7OUwM98wm91kjXiQD71jBfkqA0Fc
O91zq+DndlwWIEJE1mgck4I/CrDbzmcbLLUb+UqPKrYiQTiUqKCLcSilDHVHFsPKDcTJa5y3GJP0
rdQexwS3Rq6z7FNa7DktdDjQoaP6t7pbBfJWHceiMj5z3+vmYs6na0NOqY/FtP8CEWmK/+F3+6QV
FHkOrzPpCMjtEwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAMJx2gbBAAAA3AAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Yes
     (n=49, 17)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_106" o:spid="_x0000_s1129" style='position:absolute;
  left:12280;top:19672;width:13608;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Mismatched
     unrelated (n=43, 24)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_107" o:spid="_x0000_s1130" style='position:absolute;
  left:12280;top:17068;width:12592;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Mismatched
     related (n=52, 18)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_108" o:spid="_x0000_s1131" style='position:absolute;
  left:12268;top:18116;width:12649;height:1651;rotation:-1;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Matched
     unrelated (n=122, 70)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_109" o:spid="_x0000_s1132" style='position:absolute;
  left:12280;top:15906;width:11634;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQC9StwFwQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/disIw
FITvF3yHcATv1lTBpVSjiCC4sjdWH+DQnP5gclKSrK1vb4SFvRxm5htmsxutEQ/yoXOsYDHPQBBX
TnfcKLhdj585iBCRNRrHpOBJAXbbyccGC+0GvtCjjI1IEA4FKmhj7AspQ9WSxTB3PXHyauctxiR9
I7XHIcGtkcss+5IWO04LLfZ0aKm6l79WgbyWxyEvjc/ceVn/mO/TpSan1Gw67tcgIo3xP/zXPmkF
+WIF7zPpCMjtCwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAL1K3AXBAAAA3AAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Matched
     related (n=108, 58)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_110" o:spid="_x0000_s1133" style='position:absolute;
  left:9823;top:14992;width:6801;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Donor
     mismatch</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_111" o:spid="_x0000_s1134" style='position:absolute;
  left:12280;top:12655;width:10116;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Bone
     marrow (n=72, 43)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_112" o:spid="_x0000_s1135" style='position:absolute;
  left:12280;top:11480;width:13475;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif;color:black'>Peripheral blood (n=241, 117)</span><span
     lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_113" o:spid="_x0000_s1136" style='position:absolute;
  left:9823;top:10312;width:7112;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Stem
     Cell Source</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_114" o:spid="_x0000_s1137" style='position:absolute;
  left:12280;top:6800;width:9214;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>High
     Risk (n=102, 45)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_115" o:spid="_x0000_s1138" style='position:absolute;
  left:12280;top:7962;width:9805;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Low
     Risk<span style='mso-spacerun:yes'>  </span>(n=223, 125)</span><span
     lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_116" o:spid="_x0000_s1139" style='position:absolute;
  left:9823;top:5626;width:5169;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Risk
     stratum</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_117" o:spid="_x0000_s1140" style='position:absolute;
  left:9823;top:3289;width:9100;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Overall<span
     style='mso-spacerun:yes'>  </span>(N=325, 170)</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="624" height="482" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:468pt;
 height:361.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>NC=F, Non-Completer=Failure. With NC=F approach, subjects who discontinued from the study prior to Week 24 post-transplant or had a missing outcome at Week 24 post-transplant were counted as failures.</p><p><em>&nbsp;</em></p><p><em>P040: Prophylaxis from Week 14 (~100 days) through Week&nbsp;28 (~200 days) post-HSCT</em></p><p>The efficacy of extending letermovir prophylaxis from Week&nbsp;14 (~100 days) through Week&nbsp;28 (~200&nbsp;days) post-HSCT in patients at risk for late CMV infection and disease was assessed in a multicentre, double-blind, placebo-controlled Phase 3 trial (P040) in adult CMV-seropositive recipients [R+] of an allogeneic HSCT. Eligible subjects who completed letermovir prophylaxis through ~100&nbsp;days post-HSCT were randomised (2:1) to receive letermovir or placebo from Week 14 through Week&nbsp;28 post-HSCT. Subjects were monitored through Week&nbsp;28 post-HSCT for the primary efficacy endpoint with continued off-treatment follow-up through Week&nbsp;48 post-HSCT.</p><p>&nbsp;</p><p>Among the 218 treated subjects, 144 subjects received letermovir and 74 received placebo. The median age was 55 years (range: 20 to 74 years); 62% were male; 79% were white; 11% were Asian; 2% were Black; and 10% were Hispanic or Latino. The most common reasons for transplant were acute myeloid leukaemia (42%), acute lymphocytic leukaemia (15%), and myelodysplastic syndrome (11%).</p><p>&nbsp;</p><p>At study entry, all subjects had risk factors for late CMV infection and disease, with 64% having two or more risk factors. The risk factors included: HLA-related (sibling) donor with at least one mismatch at one of the following three HLA-gene loci: HLA-A, -B or -DR; haploidentical donor; unrelated donor with at least one mismatch at one of the following four HLA-gene loci: HLA-A, -B, -C and ‑DRB1; use of umbilical cord blood as stem cell source; use of <em>ex</em> <em>vivo</em> T-cell-depleted grafts; receipt of anti-thymocyte globulin; receipt of alemtuzumab; use of systemic prednisone (or equivalent) at a dose of &ge;1&nbsp;mg/kg of body weight per day.</p><p>&nbsp;</p><p><em>Primary efficacy endpoint</em></p><p>The primary efficacy endpoint of P040 was the incidence of clinically significant CMV infection through Week 28 post-HSCT. Clinically significant CMV infection was defined as the occurrence of either CMV end-organ disease, or initiation of anti-CMV PET based on documented CMV viremia and the clinical condition of the subject. The Observed Failure (OF) approach was used, where subjects who developed clinically significant CMV infection or discontinued prematurely from the study with viremia were counted as failures.</p><p>&nbsp;</p><p>Letermovir demonstrated superior efficacy over placebo in the analysis of the primary endpoint, as shown in Table 4. The estimated treatment difference of -16.1% was statistically significant (one-sided p-value=0.0005). Efficacy consistently favored letermovir across subgroups based on subject characteristics (age, gender, race) and risk factors for late CMV infection and disease.</p><p>&nbsp;</p><p><strong>Table 4: P040 Efficacy Results in HSCT Recipients at Risk for Late CMV Infection and Disease (OF Approach, FAS Population)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td><p><strong>Parameter</strong></p></td><td><p><strong>Letermovir</strong><br /><strong>(~200 days </strong><strong>letermovir</strong><strong>)<br />(N=144)<br />n (%)</strong></p></td><td><p><strong>Placebo<br />(~100 days </strong><strong>letermovir</strong><strong>)<br />(N=74)<br />n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Failures*</strong></p></td><td style="vertical-align:top"><p><strong>4 (2.8)</strong></p></td><td style="vertical-align:top"><p><strong>14 (18.9)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinically significant CMV infection through Week 28<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>2 (1.4)</p></td><td style="vertical-align:top"><p>13 (17.6)</p></td></tr><tr><td style="vertical-align:top"><p>Initiation of PET based on documented CMV viremia</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 1 (0.7)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 11 (14.9)</p></td></tr><tr><td style="vertical-align:top"><p>CMV end-organ disease</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 1 (0.7)</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 2 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued from study with CMV viremia before Week 28</p></td><td style="vertical-align:top"><p>2 (1.4)</p></td><td style="vertical-align:top"><p>1 (1.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Stratum-adjusted treatment difference (</strong><strong>letermovir</strong><strong> (~200 days </strong><strong>letermovir</strong><strong>)-Placebo (~100 days </strong><strong>letermovir</strong><strong>))<sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Difference (95% CI)</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>-16.1 (-25.8, -6.5)</p><p>0.0005</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* The categories of failure are mutually exclusive and based on the hierarchy of categories in the order listed.</p><p><sup>&dagger;</sup> Clinically significant CMV infection was defined as CMV end-organ disease (proven or probable) or initiation of PET based on documented CMV viremia and the clinical condition of the subject.</p><p><sup>&Dagger;</sup> 95% CIs and p-value for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (haploidentical donor yes or no). A one-sided p-value &le;0.0249 was used for declaring statistical significance.</p><p>Approach to handling missing values: Observed Failure (OF) approach. With the OF approach, failure was defined as all subjects who developed clinically significant CMV infection or discontinued prematurely from the study with CMV viremia from Week 14 (~100 days) through Week 28 (~200 days) post-HSCT.</p><p>N=Number of subjects in each treatment group.</p><p>n (%)=Number (percent) of subjects in each sub-category.</p></td></tr></tbody></table><p><!--[if supportFields]><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'><span style='mso-element:field-begin'></span></span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'><span
style='mso-spacerun:yes'> </span>INCLUDETEXT
&quot;\\\\bardsar-prod\\mk8228-cytomegalovirus\\prot001-csr\\outgraph\\pr0km0plot0cmvinfc0w24.rtf&quot;
\c MSRTF<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT </span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-separator'></span></span><![endif]--></p><p><!--[if supportFields]><span lang=EN-GB><span
style='mso-element:field-end'></span></span><![endif]-->P002: <em>Adult CMV-seronegative recipients of a kidney transplant from a CMV-seropositive donor [D+/R-]</em></p><p>To evaluate letermovir prophylaxis as a preventive strategy for CMV disease in kidney transplant recipients, the efficacy of letermovir was assessed in a multicentre, double-blind, active comparator-controlled non-inferiority Phase 3 trial (P002) in adult kidney transplant recipients at high risk [D+/R‑]. Subjects were randomised (1:1) to receive either letermovir or valganciclovir. Letermovir was given concomitantly with acyclovir. Valganciclovir was given concomitantly with a placebo to acyclovir. Randomisation was stratified by the use or non-use of highly cytolytic, anti-lymphocyte immunotherapy during induction. Letermovir or valganciclovir were initiated between Day 0 and Day 7 post-kidney transplant and continued through Week 28 (~200 days) post-transplant. Subjects were monitored through Week 52 post-transplant.</p><p>&nbsp;</p><p>Among the 589 treated subjects, 292 subjects received letermovir and 297 received valganciclovir. The median age was 51 years (range: 18 to 82 years); 72% were male; 84% were White; 2% were Asian; 9% were Black; 17% were Hispanic or Latino; and 60% received a kidney from a deceased donor. The most common primary reasons for transplant were congenital cystic kidney disease (17%), hypertension (16%), and diabetes/diabetic nephropathy (14%).</p><p>&nbsp;</p><p><em>Primary efficacy endpoint</em></p><p>The primary efficacy endpoint of P002 was the incidence of CMV disease (CMV end-organ disease or CMV syndrome, confirmed by an independent adjudication committee) through Week 52 post-transplant. The OF approach was used, where subjects who discontinued prematurely from the study for any reason or were missing data at the timepoint were not considered failures.</p><p>&nbsp;</p><p>Letermovir demonstrated non-inferiority to valganciclovir in the analysis of the primary endpoint, as shown in Table 5.</p><p>&nbsp;</p><p><strong>Table 5: P002 Efficacy results in kidney transplant recipients (OF approach, FAS population)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td><p><strong>Parameter</strong></p></td><td><p><strong>Letermovir</strong><br /><strong>(N=289)<br />n (%)</strong></p></td><td><p><strong>Valganciclovir<br />(N=297)<br />n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>CMV disease* through Week 52</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>30 (10.4)</strong></p></td><td style="vertical-align:top"><p><strong>35 (11.8)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Stratum-adjusted treatment difference (Letermovir-Valganciclovir)<sup>&dagger;</sup></strong></p><p>Difference (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>-1.4 (-6.5, 3.8)<sup>&Dagger;</sup></p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* CMV disease cases confirmed by an independent adjudication committee.</p><p><sup>&dagger;</sup> The 95% CIs for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (use/nonuse of highly cytolytic, anti-lymphocyte immunotherapy during induction).</p><p><sup>&Dagger;</sup> Based on a non-inferiority margin of 10%, letermovir is non-inferior to valganciclovir.</p><p>Approach to handling missing values: Observed Failure (OF) approach. With OF approach, participants who discontinue prematurely from the study for any reason are not considered failures.</p><p>Note: Subjects randomised to the letermovir group were given acyclovir for herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis. Subjects randomised to the valganciclovir group were given a placebo to acyclovir.</p><p>N=number of subjects in each treatment group.</p><p>n (%)=Number (percent) of subjects in each sub-category.</p></td></tr></tbody></table><p>&nbsp;</p><p>Efficacy was comparable across all subgroups, including sex, age, race, region, and the use/non-use of highly cytolytic, anti-lymphocyte immunotherapy during induction.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with PREVYMIS in one or more subsets of the paediatric population for prophylaxis of cytomegalovirus infection (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects, the pharmacokinetics of letermovir have been characterised following oral and intravenous administration. Letermovir exposure increased in a greater than dose-proportional manner with both oral or intravenous administration. The mechanism is likely saturation/autoinhibition of OATP1B1/3. The pharmacokinetics of letermovir have also been characterised following oral and intravenous administration in HSCT recipients (Table 6) and following oral administration in kidney transplant recipients (Table 7).</p><p>&nbsp;</p><p><em>Healthy</em><em> subjects</em></p><p>The geometric mean steady-state AUC and C<sub>max</sub> values were 71,500&nbsp;ng&bull;hr/mL and 13,000&nbsp;ng/mL, respectively, with 480&nbsp;mg once daily oral letermovir.</p><p>&nbsp;</p><p>Letermovir reached steady-state in 9 to 10 days with an accumulation ratio of 1.2 for AUC and 1.0 for C<sub>max</sub>.</p><p>&nbsp;</p><p><em>HSCT recipients</em></p><p>Letermovir AUC was estimated using population pharmacokinetic analyses using P001 Phase 3 data (see Table 6). Differences in exposure across treatment regimens are not clinically relevant; efficacy was consistent across the range of exposures observed in P001.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Table </strong><strong>6</strong><strong>: Letermovir AUC (ng&bull;hr/mL) values in HSCT Recipients</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Median (90% Prediction Interval)*</strong></p></td></tr><tr><td style="vertical-align:top"><p>480&nbsp;mg Oral, no cyclosporine</p></td><td style="vertical-align:top"><p>34,400 (16,900, 73,700)</p></td></tr><tr><td style="vertical-align:top"><p>480&nbsp;mg intravenous, no cyclosporine</p></td><td style="vertical-align:top"><p>100,000 (65,300, 148,000)</p></td></tr><tr><td style="vertical-align:top"><p>240&nbsp;mg Oral, with cyclosporine</p></td><td style="vertical-align:top"><p>60,800 (28,700, 122,000)</p></td></tr><tr><td style="vertical-align:top"><p>240&nbsp;mg intravenous, with cyclosporine</p></td><td style="vertical-align:top"><p>70,300 (46,200, 106,000)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* Population post-hoc predictions from the population PK analysis using Phase 3 data</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><em>Kidney transplant recipients</em></p><p>Letermovir AUC was estimated using population pharmacokinetic analysis using P002 Phase 3 data (see Table 7). Efficacy was consistent across the range of exposures observed in P002.</p><p>Table 7: Letermovir AUC (ng&bull;hr/mL) values in kidney transplant recipients</p><table border="0" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Regimen</strong></p></td><td style="vertical-align:top"><p><strong>Median (90% Prediction Interval)*</strong></p></td></tr><tr><td style="vertical-align:top"><p>480&nbsp;mg Oral, no cyclosporine</p></td><td style="vertical-align:top"><p>62,200 (28,900, 145,000)</p></td></tr><tr><td style="vertical-align:top"><p>240&nbsp;mg Oral, with cyclosporine</p></td><td style="vertical-align:top"><p>57,700 (26,900, 135,000)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* Medians and 90% prediction intervals are based on simulations using the Phase 3 population PK model with inter-individual variability.</p><p>Note: PK of letermovir was not studied following IV administration in kidney transplant recipients; however, the projected AUC following IV administration is similar to the model predicted AUC following IV administration in HSCT recipients (Table 6).</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>&nbsp;</p><p>Letermovir was absorbed rapidly with a median time to maximum plasma concentration (T<sub>max</sub>) of 1.5 to 3.0&nbsp;hours and declined in a biphasic manner. In HSCT recipients, bioavailability of letermovir was estimated to be approximately 35% with 480&nbsp;mg once daily oral letermovir administered without cyclosporine. The inter-individual variability for bioavailability was estimated to be approximately 37%. In kidney transplant recipients, bioavailability of letermovir was estimated to be approximately 60% with 480&nbsp;mg once daily oral letermovir administered without cyclosporine.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Effect of cyclosporine</em></p><p>In HSCT recipients, co-administration of cyclosporine increased plasma concentrations of letermovir due to inhibition of OATP1B. Bioavailability of letermovir was estimated to be approximately 85% with 240&nbsp;mg once daily oral letermovir co-administered with cyclosporine in patients.</p><p>If letermovir is co-administered with cyclosporine, the recommended dose of letermovir is 240&nbsp;mg once daily (see section 4.2).</p><p><strong><u>&nbsp;</u></strong></p><p><em>Effect of food</em></p><p>In healthy subjects, oral administration of 480&nbsp;mg single dose of letermovir with a standard high fat and high calorie meal did not have any effect on the overall exposure (AUC) and resulted in approximately 30% increase in peak levels (C<sub>max</sub>) of letermovir. Letermovir may be administered orally with or without food as has been done in the clinical trials (see section 4.2).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Distribution</u></p><p>&nbsp;</p><p>Based on population pharmacokinetic analyses, the mean steady-state volume of distribution is estimated to be 45.5&nbsp;L following intravenous administration in HSCT recipients.</p><p>&nbsp;</p><p>Letermovir is extensively bound (98.2%) to human plasma proteins, independent of the concentration range (3 to 100&nbsp;mg/L) evaluated, <em>in vitro</em>. Some saturation was observed at lower concentrations. Blood to plasma partitioning of letermovir is 0.56 and independent of the concentration range (0.1 to 10&nbsp;mg/L) evaluated <em>in vitro</em>.</p><p>&nbsp;</p><p>In preclinical distribution studies, letermovir is distributed to organs and tissues with the highest concentrations observed in the gastrointestinal tract, bile duct and liver and low concentrations in the brain.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>The majority of letermovir-related components in plasma is unchanged parent (96.6%). No major metabolites are detected in plasma. Letermovir is partly eliminated by glucuronidation mediated by UGT1A1/1A3.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Elimination</u></p><p>&nbsp;</p><p>The mean apparent terminal half-life for letermovir is approximately 12&nbsp;hours with 480&nbsp;mg intravenous letermovir in healthy subjects. The major elimination pathways of letermovir is biliary excretion as well as direct glucuronidation. The process involves the hepatic uptake transporters OATP1B1 and 3 followed by UGT1A1/3 catalysed glucuronidation.</p><p>&nbsp;</p><p>Based on population pharmacokinetic analyses, letermovir steady-state apparent CL is estimated to be 4.84&nbsp;L/hr following intravenous administration of 480&nbsp;mg in HSCT recipients. The inter-individual variability for CL is estimated to be 24.6%.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Excretion</u></p><p>&nbsp;</p><p>After oral administration of radio-labeled letermovir, 93.3% of radioactivity was recovered in faeces. The majority of letermovir was biliary excreted as unchanged parent with a minor amount (6% of dose) as an acyl-glucuronide metabolite in faeces. The acyl-glucuronide is unstable in faeces. Urinary excretion of letermovir was negligible (&lt;2% of dose).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Pharmacokinetics in special populations</u></p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Letermovir unbound AUC was approximately 81%- and 4-fold higher in subjects with moderate (Child-Pugh Class B [CP-B], score of 7-9) and severe (Child-Pugh Class C [CP-C], score of 10-15) hepatic impairment, respectively, compared to healthy subjects. The changes in letermovir exposure in subjects with moderate hepatic impairment are not clinically relevant.</p><p>&nbsp;</p><p>Marked increases in letermovir unbound exposure are anticipated in patients with moderate hepatic impairment combined with moderate or severe renal impairment (see section 4.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><em>Clinical study in a renally impaired population</em></p><p>Letermovir unbound AUC was approximately 115- and 81% higher in subjects with moderate (eGFR of 31.0 to 56.8&nbsp;mL/min/1.73m<sup>2</sup>) and severe (eGFR of 11.9 to 28.1&nbsp;mL/min/1.73m<sup>2</sup>) renal impairment, respectively, compared to healthy subjects. The changes in letermovir exposure due to moderate or severe renal impairment are not considered to be clinically relevant. Subjects with ESRD have not been studied.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Post-kidney transplant (P002)</em></p><p>Based on population pharmacokinetic analysis, letermovir AUC was approximately 12%, 27% and 35% higher in subjects with mild (CrCl greater than or equal to 60 to less than 90&nbsp;mL/min), moderate (CrCl greater than or equal to 30 to less than 60&nbsp;mL/min) and severe (CrCl greater than or equal to 15 to less than 30&nbsp;mL/min) renal impairment, respectively, compared to subjects with CrCl greater than or equal to 90&nbsp;mL/min. These changes are not considered to be clinically relevant.</p><p><em>&nbsp;</em></p><p><em>Weight</em></p><p>Based on population pharmacokinetic analyses in healthy subjects, letermovir AUC is estimated to be 18.7% lower in subjects weighing 80-100&nbsp;kg compared to subjects weighing 67&nbsp;kg. Based on population pharmacokinetic analysis in kidney transplant recipients (P002), letermovir AUC is estimated to be 26% lower in subjects weighing greater than 80&nbsp;kg compared to subjects weighing less than or equal to 80&nbsp;kg. These differences are not clinically relevant.</p><p>&nbsp;</p><p><em>Race</em></p><p>Based on population pharmacokinetic analyses in healthy subjects, letermovir AUC is estimated to be 33.2% higher in Asians compared to Whites. This change is not clinically relevant.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Gender</em></p><p>Based on population pharmacokinetic analyses, there is no difference in letermovir pharmacokinetics in females compared to males.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Based on population pharmacokinetic analyses, there is no effect of age on letermovir pharmacokinetics. No dose adjustment is required based on age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General toxicity</u></p><p>&nbsp;</p><p>Irreversible testicular toxicity was noted only in rats at systemic exposures (AUC) &ge;3-fold the exposures in humans at the recommended human dose (RHD). This toxicity was characterised by seminiferous tubular degeneration, and oligospermia and cell debris in the epididymides, with decreased testicular and epididymides weights. There was no testicular toxicity in rats at exposures (AUC) similar to the exposures in humans at the RHD. Testicular toxicity was not observed in mice and monkeys at the highest doses tested at exposures up to 4-fold and 2-fold, respectively, the exposures in humans at the RHD. The relevance to humans is unknown.</p><p>&nbsp;</p><p>It is known that hydroxypropylbetadex can cause kidney vacuolation in rats when given intravenously at doses greater than 50&nbsp;mg/kg/day. Vacuolation was noted in the kidneys of rats administered intravenous letermovir formulated with 1500&nbsp;mg/kg/day of the cyclodextrin excipient hydroxypropylbetadex.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Carcinogenesis</u></p><p>&nbsp;</p><p>A 6-month oral carcinogenicity study in RasH2 transgenic (Tg.RasH2) mice showed no evidence of human-relevant tumorigenesis up to the highest doses tested, 150&nbsp;mg/kg/day and 300&nbsp;mg/kg/day in males and females, respectively.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>&nbsp;</p><p>Letermovir was not genotoxic in a battery of<em> in vitro</em> or <em>in vivo</em> assays, including microbial mutagenesis assays, chromosomal aberration in Chinese Hamster Ovary cells, and in an <em>in vivo</em> mouse micronucleus study.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Reproduction</u></p><p><em>&nbsp;</em></p><p><em>Fertility</em></p><p>In the fertility and early embryonic development studies in the rat, there were no effects of letermovir on female fertility. In male rats, reduced sperm concentration, reduced sperm motility, and decreased fertility were observed at systemic exposures &ge; 3-fold the AUC in humans at the RHD (see General toxicity).</p><p>&nbsp;</p><p>In monkeys administered letermovir, there was no evidence of testicular toxicity based on histopathologic evaluation, measurement of testicular size, blood hormone analysis (follicle stimulating hormone, inhibin B and testosterone) and sperm evaluation (sperm count, motility and morphology) at systemic exposures approximately 2-fold the AUC in humans at the RHD.</p><p><u>&nbsp;</u></p><p><u>Development</u></p><p>&nbsp;</p><p>In rats, maternal toxicity (including decrease in body weight gain) was noted at 250&nbsp;mg/kg/day (approximately 11-fold the AUC at the RHD); in the offspring, decreased foetal weight with delayed ossification, slightly oedematous foetuses, and increased incidence of shortened umbilical cords and of variations and malformations in the vertebrae, ribs, and pelvis were observed. No maternal or developmental effects were noted at the dose of 50&nbsp;mg/kg/day (approximately 2.5-fold the AUC at the RHD).</p><p>&nbsp;</p><p>In rabbits, maternal toxicity (including mortality and abortions) was noted at 225&nbsp;mg/kg/day (approximately 2-fold the AUC at the RHD); in the offspring, an increased incidence of malformations and variations in the vertebrae and ribs were observed.</p><p>In the pre- and post-natal developmental study, letermovir was administered orally to pregnant rats. There was no developmental toxicity observed up to the highest exposure tested (2-fold the AUC at the RHD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxypropylbetadex (cyclodextrin)</p><p>Sodium chloride</p><p>Sodium hydroxide (E524)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Incompatible medicinal products</u></p><p>&nbsp;</p><p>PREVYMIS concentrate for solution for infusion is physically incompatible with amiodarone hydrochloride, amphotericin B (liposomal), aztreonam, cefepime hydrochloride, ciprofloxacin, cyclosporine, diltiazem hydrochloride, filgrastim, gentamicin sulphate, levofloxacin, linezolid, lorazepam, midazolam HCl, mycophenolate mofetil hydrochloride, ondansetron, palonosetron.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Incompatible intravenous bags and infusion set materials</u></p><p>&nbsp;</p><p>PREVYMIS concentrate for solution for infusion is incompatible with diethylhexyl phthalate (DEHP) plasticizers and polyurethane-containing intravenous administration set tubing.</p><p>&nbsp;</p><p>This medicinal product must not be used with other intravenous bags and infusion set materials except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial: 24 months 
After opening: Use immediately

Storage of diluted solution

Chemical and physical in-use stability has been demonstrated for 48 hours at 25 °C and for 48 hours at 2 to 8 °C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Store in original carton to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I (30&nbsp;mL) clear glass vial with a 20&nbsp;mm fluorocoated chlorobutyl stopper with aluminium flip-off cap containing 12&nbsp;mL (medium green cap) or 24&nbsp;mL (dark blue cap) of solution.</p><p>&nbsp;</p><p>Pack size: 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PREVYMIS vials are for single use only.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Preparation</u></p><p>&nbsp;</p><p>The preparation and administration instructions are the same for either dose.</p><p>&nbsp;</p><p>PREVYMIS concentrate for solution for infusion must be diluted prior to intravenous use.</p><p>&nbsp;</p><p>Inspect vial contents for discolouration and particulate matter prior to dilution. PREVYMIS concentrate for solution for infusion is a clear, colourless solution and may contain a few product-related small translucent or white particles. Do not use the vial if the solution is cloudy, discoloured or contains matter other than a few small translucent or white particles.</p><p>&nbsp;</p><p>Do not use PREVYMIS concentrate for solution for infusion with intravenous bags and infusion set materials containing polyurethane or the plasticizer diethylhexyl phthalate (DEHP). Materials that are phthalate‑free are also DEHP-free.</p><p>&nbsp;</p><p>Do not shake PREVYMIS vial.</p><p>&nbsp;</p><p>Add one single-dose vial (either 12&nbsp;mL (240&nbsp;mg dose) or 24&nbsp;mL (480&nbsp;mg dose)) of PREVYMIS concentrate for solution for infusion to a 250&nbsp;mL pre-filled intravenous bag containing either sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection or 5% dextrose, and mix the diluted solution by gentle inversion. Do not shake.</p><p>&nbsp;</p><p>Once diluted, the solution of PREVYMIS is clear, and ranges from colourless to yellow. Variations of colour within this range do not affect the quality of the product. The diluted solution should be inspected visually for particulate matter and discolouration prior to administration. Discard if the diluted solution is cloudy, discoloured or contains matter other than a few small translucent or white particles. If a vial is added to a 250&nbsp;mL intravenous diluent bag, the final concentration ranges of letermovir would be 0.9&nbsp;mg/mL (for 240&nbsp;mg dose) and 1.8&nbsp;mg/mL (for 480&nbsp;mg dose).</p><p>&nbsp;</p><p><u>Administration</u></p><p>&nbsp;</p><p>See section 4.2.</p><p><strong><u>&nbsp;</u></strong></p><p>PREVYMIS diluted solution must be administered through a sterile 0.2&nbsp;micron or 0.22&nbsp;micron polyethersulfone (PES) in-line filter.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Compatible intravenous solutions and other medicinal products</u></p><p>&nbsp;</p><p>PREVYMIS concentrate for solution for infusion is compatible with 0.9% sodium chloride and 5% dextrose solutions.</p><p>&nbsp;</p><p>PREVYMIS should not be co-administered through the same intravenous line (or cannula) with other medicinal products and diluent combinations except those listed below.</p><p><strong>&nbsp;</strong></p><p><strong>List of compatible medicinal products when PREVYMIS and medicinal products* are prepared in 0.9% sodium chloride</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ampicillin sodium</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluconazole</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ampicillin sodium/Sulbactam sodium</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Human insulin</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-thymocyte globulin</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium sulfate</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caspofungin</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Daptomycin</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Micafungin</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fentanyl citrate</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*Refer to the prescribing information to confirm compatibility of simultaneous co-administration.</p><p>&nbsp;</p></td></tr></tbody></table><p><strong>List of compatible medicinal products when PREVYMIS and medicinal products* are prepared in 5% dextrose</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amphotericin B (lipid complex)<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrocortisone sodium succinate</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anidulafungin</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Morphine sulfate</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cefazolin sodium</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Norepinephrine bitartrate</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ceftaroline</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pantoprazole sodium</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ceftriaxone sodium</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium chloride</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Doripenem</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium phosphate</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Famotidine</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tacrolimus</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Folic acid</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Telavancin</p></td></tr><tr><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ganciclovir sodium</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tigecycline</p></td></tr></tbody></table><p>&nbsp;</p><p>*Refer to the prescribing information to confirm compatibility of simultaneous co-administration.</p><p><strong><sup>&dagger;</sup></strong>Amphotericin B (lipid complex) is compatible with PREVYMIS. However, Amphotericin B (liposomal) is incompatible<em> </em>(see section 6.2).</p><p><strong><u>&nbsp;</u></strong></p><p><u>Compatible intravenous bags and infusion set materials</u></p><p>&nbsp;</p><p>PREVYMIS is compatible with the following intravenous bags and infusion set materials. Any intravenous bags or infusion set materials not listed below should not be used.</p><p>&nbsp;</p><p><em>Intravenous bag materials</em></p><p>Polyvinyl chloride (PVC), ethylene vinyl acetate (EVA) and polyolefin (polypropylene and polyethylene)</p><p>&nbsp;</p><p><em>Infusion set materials</em></p><p>PVC, polyethylene (PE), polybutadiene (PBD), silicone rubber (SR), styrene&ndash;butadiene copolymer (SBC), styrene-butadiene-styrene copolymer (SBS), polystyrene (PS)</p><p><em>&nbsp;</em></p><p><em>Plasticizers</em></p><p>Tris (2-ethylhexyl) trimellitate (TOTM), butyl benzyl phthalate (BBP)</p><p>&nbsp;</p><p><em>Catheters</em></p><p>Radiopaque polyurethane</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder
Merck Sharp & Dohme BV
Waarderweg 39
PO Box 581       
2031 BN, 2003 PC 
Haarlem           
Netherlands

Manufacturer
MSD International GmbH
T/A MSD Ireland (Carlow)
Dublin Road,
Carlow, Co. Carlow
Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>